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Atherosclerosis and its implications are the leading cause of death worldwide. 
Current treatment options fail to prevent and cure atherosclerosis completely. Therefore, 
new therapeutic options based on newly-discovered pro- and anti-inflammatory pathways 
linking lipid and inflammation biology are needed. Atherosclerosis is a chronic 
inflammatory process of the arterial wall that typically occurs at sites with disturbed blood 
flow (d-flow), such as curved and branched areas in the vasculature. Unidirectional, 
laminar shear stress upregulates atheroprotective genes, whereas d-flow, characterized as 
low and oscillatory shear stress, upregulates a number of pro-atherogenic genes which 
promotes atherosclerosis. In particular, KLK10 (Kallikrein-10) is one of the most important 
atheroprotective genes identified recently in our lab. Therefore, targeted delivery of 
KLK10 gene to dysfunctional endothelial cells might be an effective way to inhibit 
atherosclerotic development. However, there is still a lack of a method for targeted 
transgene expression in arterial endothelium in vivo. Ultrasound imaging is one of the most 
common imaging for the diagnosis of atherosclerosis in clinic. Ultrasound combined with 
gas-filled microbubbles has been widely reported to enhance transgene expression both in 
vitro and in vivo. In this thesis, we established two technologies based on the sonoporation 
effect by microbubble destruction with ultrasound for the transgene expression of KLK10 
in vivo to inhibit atherosclerosis. 
Besides its traditional functions, skeletal muscle has been discovered to be an 
endocrine organ, secreting a lot of myokines to act on several organs. The use of highly 
vascularized muscle as an endocrine organ for the systemic administration of therapeutic 
proteins is a really interesting application. Therefore, we firstly established a method to 
induce transgene expression of KLK10 in skeletal muscle to inhibit atherosclerosis. After 
intramuscular injection of naked plasmid and microbubbles, ultrasound is applied to the 
 xv 
injecting site to induced increased transgene expression in the skeletal muscle. By adding 
a signal peptide to the N-terminal of coding sequence of KLK10, the expressed KLK10 
proteins can be secreted out, enter into the blood, and act on the inflamed area to inhibit 
atherosclerosis. After optimizing the ultrasound parameters, the ultrasound-enhanced 
transgene expression in skeletal muscle is increased by over 10 fold compared with naked 
plasmid injection and can persist for over 3 weeks. The transgene expression of KLK10 in 
skeletal muscle reduced the atherosclerotic lesions from 64.6% to 18.0% in the partial 
carotid ligation model. These results demonstrated the ultrasound-enhanced transgene 
expression of KLK10 in skeletal muscle as a potential therapy for atherosclerosis. 
Although the transgene expression of KLK10 in skeletal muscle can inhibit 
atherosclerosis, the expressed KLK10 proteins can act on the whole body, not the artery 
endothelium alone, which may cause some unexpected side effects. Therefore, we sought 
to establish a method for targeted gene delivery to arterial endothelium. Adeno-associated 
virus (AAV) is currently among the most frequently-used gene vectors for gene therapy 
characterized with lack of pathogenicity, persistence of transgene expression, and the many 
available serotypes. However, AAV alone is not able to transfect arterial endothelial cells 
in vivo after system administration. Therefore, we established a simple but highly effective 
technology for imaging-guided gene delivery to mouse artery combining ultrasound 
imaging, microbubbles and AAV gene vector. 
With color Doppler imaging, the anatomical structure of artery can be visualized 
and the area of interest can be selected so that ultrasound only irradiate the selected area. 
After microbubbles injection, the ultrasound can destroy the microbubbles only in the 
selected areas, resulting increased permeability of the artery. Following system 
administration, AAV gene vector can preferentially accumulate in the ultrasound-treated 
area, resulting in highly enhanced transgene expression. The transgene expression in 
carotid endothelium induced by this ultrasound-guided method is positively related to 
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ultrasound power and dose of microbubbles. The mechanical index of ultrasound at 0.4 and 
dose of microbubbles at 5×109/kg was selected for further experiments. The time interval 
between microbubbles and AAV injection is also optimized. No significant differences in 
transgene expression was found when the time interval was shorter than 3 h, but the 
expression was much reduced when the time interval was longer than 12 h. The ultrasound-
guided method also induced highly enhanced transgene expression in media and adventitia 
layer, but ~5 days later than that in endothelium. The gene expression in both endothelium 
and media and adventitia could persist for at least 8 weeks. At 4th week, the ultrasound 
treatment increased transgene expression by ~18 times in endothelium, while ~85 times in 
media and adventitia. By labelling AAV with fluorescent dyes, the distribution of AAV in 
artery wall was determined. Without ultrasound treatment, AAV could only temporally 
bind to arterial endothelium in big aggregates and was flushed away very soon. However, 
when the artery is permeabilized by ultrasound in combination with microbubbles, large 
amounts of AAV could be well dispersed in both intima and media layer and persist for a 
longer time. This explained the reason why ultrasound in combination with microbubbles 
could highly increase transgene expression in arteries by AAV. The ultrasound-guided 
method can also be used for targeted transgene expression in both abdominal aorta and 
femoral artery. After selectively treating the suprarenal abdominal aorta or infararenal aorta 
with ultrasound combining with microbubbles and AAV, the gene was only expressed in 
the ultrasound-treated areas. Similarly, the ultrasound treatment also increased transgene 
expression in femoral artery by ~58 times. These results demonstrated the novel technique 
for targeted gene delivery to artery wall in a noninvasive image-guided way. 
Finally, the ultrasound imaging-targeted method was used for targeted delivery of 
KLK10 to inhibit atherosclerosis. After partial carotid ligation surgery, the KLK10 
expression in the left common carotid artery (LCA) is reduced compared with the right 
common carotid artery (RCA). After treating LCA with ultrasound combining with 
 xvii 
microbubbles, KLK10-encoding AAV9 at a dose of 2.5×1013vg/kg could increase the 
expression of KLK10 in LCA to a level comparable to that in RCA. In the atherosclerotic 
studies, the targeted delivery of KLK10 gene with this technology could significantly 
reduce the plaque size, CD45, and VCAM1 expression without inducing any significant 
changes in the plasma lipid profile. This demonstrated that ultrasound imaging-guided 
delivery of KLK10 can inhibit atherosclerosis.  
In summary, this thesis established two technologies for transgene expression of 
KLK10 in vivo to inhibit atherosclerosis. This research not only highlights the potential of 
KLK10 for the gene therapy of atherosclerosis, but also provides two important methods 
of gene delivery, which may find their broad applications in fundamental studies and 
clinical translation in respect to artery diseases, such as atherosclerosis, AAA, and PAD. 
 
 1 
CHAPTER 1. INTRODUCTION 
This thesis aims at establishing an ultrasound-guided method for gene delivery to 
inhibit atherosclerosis. In this chapter, a brief introduction of background knowledge was 
given, including the biology of atherosclerosis, KLK10 as a novel mechanosensitive gene, 
current targeting strategies for atherosclerosis, ultrasound for the therapy and diagnosis of 
atherosclerosis, skeletal muscular gene delivery, and AAV as a gene vector. After that, the 
significance and innovations of this research is summarized. Finally, the overall 
organization of this thesis is summarized. 
1.1 Background 
1.1.1 Biology of atherosclerosis  
Figure 1.1 Stages in the development of atherosclerosis. [22] 
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Atherosclerosis is implicated as the key pathogenesis of cardiovascular disease, and 
a leading cause of death worldwide[1]. Current treatment options of atherosclerosis include 
lifestyle modifications (diet, exercise, etc.), statins, and surgical procedures [2-8]. However, 
these methods fail to prevent and cure atherosclerosis completely. Therefore, new 
therapeutic options based on newly-discovered pro- and anti-inflammatory pathways 
linking lipid and inflammation biology are needed [9-16]. 
Atherosclerosis is a chronic inflammatory process of the arterial wall that typically 
occurs at sites with disturbed blood flow (d-flow), such as curves and branches in the 
vasculature. Blood flow generates shear stress on mechano-sensors, which transduce sheer 
stress into cell signaling events and ultimately changes gene expression in vascular 
endothelial cells. Unidirectional, laminar shear stress (LS, or s-flow) upregulates 
atheroprotective genes such as Klf2, Klf4 and eNOS, whereas d-flow, characterized as low 
and oscillatory shear stress (OS), upregulates a number of pro-atherogenic genes including 
matrix metalloproteinase (MMP), and vascular cell adhesion molecule-1 (VCAM-1), 
which promotes atherosclerosis[17-19]. The dysfunctional endothelial cells initiates and 
perpetuates the plaque by recruiting monocytes from circulating blood. The atherosclerotic 
plaque is characterized by accumulation of lipids in the artery wall, together with 
infiltration of immunocytes, such as macrophages, and the formation of a fibrous cap by 
vascular smooth muscle cells[20]. Plaque growth can cause flow-limiting stenosis that may 
lead to tissue ischemia. Plaque ruptures trigger thrombosis, leading to exposure of 
thrombogenic materials in the core, followed by platelet aggregation, humoral coagulation 
and formation of a thrombus that may either interrupt blood flow locally or embolize and 
lodge in distal arteries [21]. Endothelial cells play a key role in the initializing and 
development of atherosclerosis, and thus normalizing dysfunctional endothelial cells by 
upregulating atheroprotective genes and downregulating pro-atherogenic genes can be an 
effective way to prevent and cure atherosclerosis. 
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1.1.2 KLK10 as a novel mechanosensitive gene 
In response to s-flow or d-flow, hundreds of mechanosensitive genes in endothelial 
cell were down- or up-regulated. Therefore, to discover novel mechanosensitive genes and 
uncover their roles in the development of atherosclerosis is a hotpot in atherosclerotic 
studies and may provide novel therapeutic and diagnostic targets of atherosclerosis. 
Investigators have conducted DNA microarray studies with cultured endothelial cells 
exposed to different shear conditions [22-31] and have identified numerous mechanosensitive 
genes, including Klf2, Klf4 , eNOS, bone morphogenic protein 4 (BMP4), angiopoietin-2 
(Angpt2) , VCAM1, ICAM1, and cathepsins. The following functional studies also 
uncovered the important role of these mechanosensitive genes in the development of 
inflammation, thrombosis, angiogenesis, and atherosclerosis [32-39].  
However, the in vitro shear conditions cannot exactly simulate in vivo conditions. 
Our group previously established an accurate atherosclerotic model by partial carotid 
ligation (Figure 1.2)[17]. Three of four caudal branches of left common carotid artery (LCA) 
are ligated, leaving superior thyroid artery intact. The contralateral right common carotid 
artery (RCA) serves as internal control. The partial carotid ligation surgery causes d-flow 
in LCA, which rapidly induce atherosclerosis. Furthermore, we also developed a simple 
method to isolate endothelial cells-enriched RNA samples that are free of contamination 
of smooth muscle cells and leukocytes. With these two technologies, we conducted 
microarray studies using carotid endothelium exposed to d-flow[40]. More than 500 
mechanosensitive genes that change in response to disturbed flow within 2 days were 
identified. Several important novel mechanosensitive genes were found, such as Lmo4, 
Fosl2, Id1, Jam2, Klk10, and Dhh. 
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Figure 1.2 Partial carotid ligation surgery induces disturbed flow. (A) Paradigm illustrates 
the partial carotid ligation surgery. Three branches of the LCA [occipital artery (OA), 
internal carotid artery (ICA), and external carotid artery (ECA)] were ligated, while the 
superior thyroid artery (STA) is left intact. (B) Ultrasound shows the flow profiles of the 
carotid artery after the surgery. (C) Quantification of the blood flow post the surgery. 
Shown are means ± SE, n = 4 experiments.[17] 
Based on our microarrays studies, KLK10 (Kallikrein-10) is one of the genes that 
are most sensitive to blood flow changes[41]. KLK10 is one of the fifteen kallikrein 
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subfamily members located in a cluster on chromosome 19. The KLK10 is a secreted serine 
protease and have been implicated to plays a key role in suppressing the tumorigenesis of 
breast, ovarian, colorectal, and prostate cancers [42-44]. Our recent studies found that KLK10 
is a very important atheroprotective gene, which is down-regulated significantly by d-flow 
both in vitro and in vivo. Therefore, locally increasing the gene expression of KLK10 in 
the areas influenced by d-flow might be an efficient way for the therapy of atherosclerosis. 
However, there is still no effective way for targeted delivery of KLK10 in vivo. 
1.1.3 Targeted-delivery strategies for atherosclerosis 
The atherosclerotic plaque is primarily made of fatty substances and leukocytes, 
especially the blood monocytes and tissues macrophages. The predominant cell type is 
macrophage. Due to its involvement in atherosclerosis and intrinsic nature of engulfing 
external substances, macrophage is the most common target cell type used for targeted-
delivery of therapeutic agents for atherosclerosis. Lipoproteins, such as high density 
lipoproteins (HDL) and low density lipoproteins (LDL), are nature nanoparticles targeting 
to macrophages. The primary function of lipoproteins in the body is transporting 
cholesterol and other lipids. The lipoproteins are composed of a hydrophobic core of 
triglycerides and cholesterol esters encapsulated with a phospholipid/cholesterol mixed 
layer, into which apolipoproteins are embedded. Its natural targeting capability and the 
option to incorporate lipophilic payloads, such as imaging and therapeutic agents, in both 
the hydrophobic core and the phospholipid shell make the lipoproteins an attractive 
nanocarrier[45]. Willem J. M. Mulder et al. demonstrated statin-loaded HDL nanoparticles 
could specifically deliver statins to plaque macrophages, thereby inhibiting their 
proliferation and reducing inflammation (Figure 1.3)[46]. These therapeutic anti-
inflammatory benefits can be maintained by a subsequent 8-week oral statin treatment[47]. 
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Figure 1.3 Deliver statin to the plaque macrophages with HDL. (A) Schematic illustration 
of HDL nanoparticles with or without statin ([S]-rHDL and rHDL). (B) Thickness of the 
vessel wall changes after receiving low-dose [S]-rHDL, blank rHDL, statin, and placebo 
over a period of 12 weeks. (C) Plaque area of mice after receiving different treatments. (D) 
CD68-positive area in the plaque after receiving different treatments. [48] 
Although lipid transport primarily occurs in macrophages and other phagocytic 
cells, vascular smooth muscle cells (VSMCs) also play a key role in lipid accumulation[11]. 
A recent study by Bo Tang et al. developed a VSMC-targeted copper sulfate nanoparticles 
as a photothermal switch (Figure 1.4)[49]. The nanoparticles could specifically accumulate 
in VSMCs by coating the nanoparticles with an antibody against TRPV1, a cation channel, 
which is highly expressed in plaque VSMCs. Local temperature increase can be induced 
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by NIR laser irradiation. The heat-activation of TRPV1 could activate autophagy and 
reduce lipid accumulation. Injection of the NPs in vivo in ApoE−/− mice followed by laser 
irradiation greatly reduced plaque formation. This research demonstrated a simple yet 
highly effective strategy for precise in vivo targeting and controlling of lipid-processing 
process, which is important for the atherosclerosis. 
Figure 1.4 Schematic illustration of CuS-TRPV1 as a photothermal switch for activation 
of TRPV1 signaling to inhibit atherosclerosis.[49] 
Endothelial cells form the outlayer of atherosclerosis plaque and play a key role in 
the initiation and progression of atherosclerosis. Therefore, normalizing the dysfunctional 
endothelial cells is another promising therapy of atherosclerosis. Our group devised a 
liposome formulation for targeted delivery of anti-miR-712 to the plaques of ApoE−/− mice 
(Figure 1.5)[50]. The liposome is decorated with VHPK peptide, a VCAM1-internalizing 
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peptide, which helps the liposome not only bind to VCAM1 but also internalized by 
inflamed endothelial cells. The encapsulation allowed for potent in vivo downregulation of 
miR-712 at a dose 80% lower than if given freely without lipid encapsulation. 
 
Figure 1.5 Multifunctional liposome formulation for targeted delivery of anti-miR-712 to 
the plaques of ApoE−/− mice.[50] 
Although several strategies are developed for the targeted-delivery of various 
therapeutic agents, including chemical drugs, RNA and proteins, targeted-delivery of DNA 
gained very limited success[51]. DNA-based gene therapy holds several advantages 
compared with protein- and RNA- based therapy. DNA plasmids are easier and cheaper 
and if delivered properly the therapeutic effect can last for a much longer time than proteins 
and RNA.  
1.1.4 Ultrasound for imaging and therapy of atherosclerosis 
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Ultrasound is sound waves with a frequency higher than those audible to humans. 
Ultrasound imaging utilizes the interaction of sound waves with living tissue to produce an 
image of the tissue or determine the velocity of blood in Doppler-based modes. 
Quantitative structural and functional information of the target organ can be obtained by 
analyzing these dynamic, real-time images[52]. This versatile, noninvasive diagnostic tool 
is widely used in clinic as one of the four most common imaging methods (ultrasound 
imaging, CT, MRI and PET). Ultrasound imaging is also widely used for diagnosis and 
risk assessment of atherosclerosis. In addition to imaging, ultrasound can also be used for 
therapy. Ultrasound, when combined with some specific ultrasound-responsive materials, 
can produce effects on selected cells or tissues, and thus has been developed for the therapy 
of a lot of diseases, including cancer[53], neurodegenerative diseases[54, 55] and 
atherosclerosis[56]. 
1.1.4.1 Ultrasound imaging of atherosclerosis 
Ultrasound as a cheap, noninvasive, non-ionizing and real-time imaging technique 
is an ideal tool for progress monitoring of atherosclerosis [57-62]. Intima-media thickness 
(IMT), the distance between the lumen-intima interface and the media-adventitia interface 
of the arterial wall (Figure 1.6), is widely studied as a surrogate marker for detecting 
subclinical atherosclerosis for risk assessment and monitoring the progress of 
atherosclerosis for medical intervention[63-65]. High-frequency ultrasound produce the high 
spatial resolution required to measure IMT in vessel walls. However, higher frequency also 
limits tissue penetration of ultrasound. Therefore, this kind of ultrasound examination is 
limited to vessels close to skin, such as carotid artery. In addition to IMT, ultrasound 
imaging can also be used to quantify the carotid plaque burden, which has been developed 
as a promising alternative to carotid IMT (CIMT) measurements. Carotid plaque burden 
can be measured as total plaque area or total plaque volume. Compared with CIMT, plaque 
burden has been demonstrated as a better risk predictor of cardiovascular diseases[66]. 
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Besides the anatomical information, addition information can be obtained from ultrasound 
images. Plaques containing a large lipid core appear echolucent, while plaque fibrosis and 
calcification tend to appear echogenic. Based on the echolucency, carotid plaques can be 
classified into four categories as echolucent, predominantly echolucent, predominantly 
echogenic, and echogenic[67]. In patients with carotid stenosis, the degree of plaque 
echolucency is correlated with increased risk for cerebral ischemic symptoms[68]. 
Figure 1.6 Longitudinal view of carotid artery shows IMT. The IMT is the distance 
between two echogenic lines at the far wall representing the lumen-intima interface and 
media-adventitia interface (arrows).[66] 
Ultrasound contrast agents were developed in the early 1990s with the goal of better 
delineation of the left ventricular endocardial border[69]. With technique advances, the most 
popular contrast agents used in clinic nowadays are microbubble-based contrast agents 
composed of large-molecular-weight hydrophobic gases such as sulfur hexafluoride or 
perfluorocarbons encapsulated with a thin phospholipid shell. These microbubbles measure 
on average 1–2 µm in diameter and thus can circulate freely throughout the blood. 
Microbubbles undergo volumetric oscillations with compression during the pressure peaks, 
and expansion during the pressure nadirs of an incident ultrasound wave. These volumetric 
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oscillations result in a strong backscattered acoustic signal that can be detected by 
ultrasound systems. With the aid of this kind of contrast-enhanced ultrasound imaging, the 
sensitivity and specificity for plaque ulceration and neovascularization is increased[70, 71]. 
The distribution of ulceration and neovascularization provides additional information for 
assessment of plaque vulnerability.. 
Figure 1.7 Ultrasound molecular imaging with acoustic radiation force (ARF). (A) 
Schematic diagram illustrating the modulated ARF-based imaging. (B) The experimental 
setup of mice and probe for ARF imaging. (C) A representative image of the mouse 
abdominal aorta. [75] 
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Another promising application of contrast imaging is the specific attachment of 
microbubbles to a target of interest. For example, the ligands targeting activated endothelial 
cells or leukocytes can be coupled to the surface of microbubbles via a polyethylene glycol 
(PEG) spacer[72]. Protocols for this kind of ultrasound molecular imaging usually involve 
intravenous bolus injections of targeting microbubbles[73]. Over several minutes, some 
microbubbles will adhere to a target of interest within tissue, while other un-attached 
microbubbles are cleared from the circulation. After destruction of the microbubbles with 
high-power ultrasound pulses, the presence of attached microbubbles can be derived by 
comparing images before and after microbubbles destruction. An ultrasound image of these 
attached microbubbles provide information about the level of expression of the target in 
tissues. Although promising, molecular ultrasound imaging at current status is still far away 
from clinical adoption for two main reasons. On one hand, the targeting microbubbles with 
high specificity is still not applicable in clinic due to the complex fabrication procedure 
and low stability of microbubbles. On the other hand, the length (30-40 min) and 
complexity of the existing molecular imaging protocols could delay clinical adoption and 
increase procedure costs[74]. Recently, Shiying Wang et.al. reported a novel molecular 
imaging method, referred to as modulated acoustic radiation force (ARF)-based imaging, 
for rapid assessment of P-selectin and VCAM-1 in the abdominal aorta of mice in just 180 
seconds (Figure 1.7)[75]. This method might have the potential for clinical translation with 
considerable further improvement and validation. 
1.1.4.2 Ultrasound for the therapy of cardiovascular disease 
While low and intermediate acoustic pressure results in linear and non-linear 
oscillations of microbubbles, at high acoustic powers, microbubbles can be destroyed by 
either outward diffusion of the gas during the compression phase, diffusion from large shell 
defects, or from complete fragmentation of microbubbles. Microbubble destruction during 
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high-power ultrasound can lead to increased permeability of cell membranes, which may 
facilitate gene or drug delivery. 
Figure 1.8 Local delivery of plasmid DNA into rat carotid artery using ultrasound in a 
restenosis model induced by balloon injury. (A) Schematic illustration of transfection of 
naked plasmid DNA using ultrasound with Optison into intact or balloon-injured blood 
vessels in vivo. Comparison of luciferase activity is shown after in vivo transfection into 
intact blood vessels (B) and ballooninjured blood vessels (C).[76] 
Yoshiaki et al. reported an ultrasound transfection method with enhanced 
transfection efficiency of naked plasmid DNA into blood vessels (Figure 1.8)[76]. Plasmid 
mixed with Optison, a commercial microbubble agent, could significantly increase 
transfection efficacy in cultured human VSMC and ECs in vitro. Furthermore, they tested 
the method to transfect the artery in vivo. They induced the vascular injury of the common 
carotid with a balloon catheter. The injured segment was transiently isolated by temporary 
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ligatures. Then the isolated vessel was incubated with Optison and plasmid within the 
lumen, and then treated with ultrasound. With this method, significantly higher luciferase 
activity was detected in carotid artery transfected with Optison and ultrasound than with 
plasmid alone. In addition, transfecting the carotid artery with p53 gene utilizing this 
method could significantly reduce the intimal-to-medial area ratio in rats two weeks after 
balloon injury. This research highlighted the high efficacy of the sonoporation in enhancing 
gene delivery. However, this method requires complicated surgery procedures and cause a 
lot of pain to animals, thus limiting its wide applications. 
Recently, Xiaowei Wang et al. developed a VCAM-1-targeted miR-126-loaded 
microbubble as a theranostic agent for early diagnosis and long-sought-after medical 
therapy of AAA  (Figure 1.9) [77].  In this research, microbubbles are linked with VCAM1-
targeted single-chain antibody, while miR-126 is tagged with cholesterol to insert in the 
lipid membrane of microbubbles. After intravenous injection, this microbubbles can 
selectively bind to inflamed endothelial cell, in which VCAM-1 is highly expressed. The 
ultrasound is then applied to destroy the microbubbles and the released miR-126 will enter 
adjacent cells. With this method, the development of AAA in an angiotensin-II-induced 
mouse model can be prevented. 
Hong Jin et al. also reported ultrasound-targeted microbubbles could deliver miR-
21 into carotid plaques rescued the vulnerable plaque rupture phenotype without off-target 
effects[78].  The miR-21 is electrostatically bind to the charged microbubbles.  This 
ultrasound-targeted local delivery of miR-21 could enhance the accumulation of miR-21 
in plaque, and thereby stabilizes fibrous caps in vulnerable atherosclerotic lesions. 
Compared with systemic forms of injection without ultrasound and microbubbles, this 
ultrasound-targeted delivery show reduced off-target effects in liver and brain. 
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Figure 1.9 Schematic illustration of dual-targeted delivery of miR-126 to inflamed 
endothelial cells.[77] 
In addition of enhancing gene of drug delivery, another promising therapy of 
atherosclerosis with ultrasound is sonodynamic therapy (SDT), which utilizes ultrasound 
to locally activate sonosensitizers to induce cell death. Low-intensity SDT stabilized early 
atherosclerotic plaques by inducing macrophage apoptosis and apoptotic cell clearance[56]. 
A recent study by Ye Tian et al. shows that SDT efficiently decreased the atherosclerotic 
burden within 1 week in atherosclerotic rabbit and ApoE-deficient mouse models[79]. 
Compared with atorvastatin, the standard of care for atherosclerosis, SDT showed more 
significant plaque shrinkage and lumen enlargement during 1 week treatment. In a pilot 
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clinical trial recruiting the patients suffering atherosclerotic peripheral artery disease, 
combination therapy of SDT with atorvastatin efficiently reduced progression of 
atherosclerotic plaque within 4 weeks, and its efficacy was able to last for at least 40 weeks. 
1.1.5 Skeletal muscular gene delivery 
Figure 1.10 Physiological consequences of the production and release of myokines on 
skeletal muscle and other organs.[86] 
Gene transfer for gene therapy is a rapidly expanding field. Tissues with high 
transgene efficacy is sought including tumors, and organs such as the liver, heart, or brain 
[80-82]. Special interest has been devoted to gene delivery to skeletal muscle fibers, for the 
correction of myopathies, local secretion of angiogenic or neurotrophic factors, and 
vaccination [83-85]. Besides its traditional functions, skeletal muscle has been discovered to 
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be an endocrine organ, secreting a lot of myokines to act on several organs(Figure 1.10)[86]. 
Therefore, the use of highly vascularized muscle as an endocrine organ for the systemic 
secretion of therapeutic proteins is a really interesting application.  
Deposition of extracellular matrix is the major cause of fibrosis, which may destroy 
the function of tissues involved, such as kidney, liver, heart, etc. Overproduction of 
transforming growth factor-β1 (TGF-β1), induced by injury or disease, is thought to be the 
underlying reason for extracellular matrix deposition. Therefore, inhibiting TGF-β1is an 
effective way for the therapy of fibrosis. Yoshitaka Isaka et al. found that skeletal muscle 
expression of decorin, an inhibitor of TGF-β1, could prevent fibrotic disease in rat model 
of glomerulonephriti [87]. The gene transfer into skeletal muscle is achieved with the method 
of combining plasmid with a mixture of hemagglutinating virus of Japan and liposome. 
The gene transfer into rat skeletal muscle increases the amount of decorin expression in 
skeletal muscle and decorin present in kidney. This resulted in a significant reduction in 
levels of glomerular TGF-β1 expression, extracellular matrix accumulation and proteinuria. 
This research highlights the transgene expression in skeletal muscle as a potential therapy 
for fibrosis induced by TGF-β1. 
Human apolipoprotein E (ApoE) is a secreted plasma protein playing an important 
role in removing remnant lipoproteins and in transporting cholesterol from peripheral 
tissues to liver. Therefore, deficiency of ApoE causes severe hypercholesterolemia and 
atherosclerotic development. Takis Athanasopoulos et al. found that intramuscular 
injection of a plasmid vector expressing human apolipoprotein E (ApoE) in ApoE deficient 
mouse could limit atherosclerosis in aorta[88]. Emanuela Signori et al. reported that 
intramuscular injection of naked plasmid vector encoding human ApoE could reduce 
severe hypercholesterolemia in newborn mice and when the DNA is injected early, no 
immune response is generated, allowing repeated injections[89]. These researches indicate 
the potential applications of intramuscular gene transfer for the therapy of atherosclerosis. 
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Although intramuscularly injecting naked plasmid can transfer a foreign gene into 
muscle fibers, this method holds several major limitations, such as low efficiency, lack of 
reproducibility. Thus, alternative strategies aiming at the level and reliabilities of skeletal 
muscular gene expression are needed. Several physical method such as electroporation, 
sonoporation, and magnetofection have been developed with enhanced efficacy.  
Galina Shapiro et al. used nonlinear ultrasound and bioluminescence imaging to 
optimize the acoustic pressure, microbubble concentration, treatment duration, DNA 
dosage, and number of treatments required for in vivo luciferase gene expression in a 
mouse thigh muscle model[90]. Mice injected with 50 μg luciferase plasmid DNA and 5 × 
105 microbubbles followed by ultrasound treatment at 1.4 MHz, 200 kPa, 100-cycle pulse 
length, and 540 Hz pulse repetition frequency (PRF) for 2 min exhibited superior transgene 
expression compared to all other treatment groups. They found that localized ultrasound-
mediated, microbubble-enhanced gene delivery to endogenous mesenchymal progenitor 
cells could effectively induce efficient bone regeneration and fracture repair in mini-pigs, 
thereby addressing a major orthopedic unmet need and offering new possibilities for 
clinical translation[91]. 
1.1.6 Adeno-associated virus (AAV) as an gene vector for gene therapy 
AAV is currently among the most frequently used gene vectors for gene therapy 
characterized with lack of pathogenicity, persistence of transgene expression, and the many 
available serotypes. Up to now, AAV vectors have been used in over 238 clinical trials 
worldwide, approximately 8.1% of gene therapy clinical trials[92]. In 2017, the United 
States Food and Drug Administration (FDA) approved the LUXTURNA™ from Spark 
Therapeutics as the first gene therapy product for the eye. 
AAV was originally found as a contaminant of adenovirus preparations. AAV is 
about 20 nm in diameter made of a protein shell surrounding a sing-stranded DNA genome 
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of about 4.8 kb. The viral genome contains three genes, Rep, Cap, and aap, flanked by two 
internal terminal repeats (ITR). Rep is essential for viral genome replication and packaging, 
while Cap encodes viral capsid proteins (VP1/VP2/VP3). The aap gene expresses the 
assembly-activating protein, which is thought to assist in capsid assembly. The viral capsid 
is composed of 60 proteins assembled in a molar ratio of 1:1:10 (VP1:VP2:VP3) to form 
an icosahedral structure. For gene delivery applications, the coding sequences of viral 
genome is replaced by a promoter and the gene of interest. It is believed that the ITR-
flanked transgene can form non-integrated non-replicating episomes that persists in 
nucleus of cells. Several clinical trials for hemophilia, heart failure, and lipoprotein lipase 
deficiency and so on have demonstrated that AAV gene transfer can result in sustained 
therapeutic effects for several years.[93-95] 
Local delivery of AAV can maximize concentration and residence time of the gene 
vector in close to the target cells, avoiding wide biodistribution. This is useful for several 
tissues, including eye, cardiac muscle, skeletal muscle, and central neural system. However, 
there are also many diseases or applications requiring system delivery, as the target sites 
are not accessible with local delivery, for example, atherosclerosis.  Systemic 
administration of AAV of results in a significant accumulation in the liver and also other 
cells and tissues types. To restrict expression to only the liver, a common method is to use 
the liver-specific promoter [96-100]. Our group has previously reported to deliver PCSK9 
gene driven by a liver-specific promoter with AAV, which could induce hyperlipidemia. 
By combining this technology with partial carotid ligation surgery, an accelerated model 
of atherosclerosis was developed in C57 mice[81]. Compared with the control, PCSK9 
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delivery could result in increased serum PCSK9, hypercholesterolemia, and accelerated 
atherosclerosis development in three weeks. 
Figure 1.11 The paradigm of Acoustically Targeted Chemogenetics (ATAC). [80] 
To deliver gene to specific cells or tissues with AAV often requires specially 
designed promoters or modified capsid protein. Despite some success, these methods are 
usually limited by low efficacy, lack of highly specific promoters or targeting ligands, and 
off-target effects. Jerzy O. Szablowski et al. reported a concept named as Acoustically 
Targeted Chemogenetics (ATAC) to spatially control gene expression in brain for the non-
invasive modulation of neural circuits (Figure 1.11)[80]. In this method, the blood-brain 
barrier (BBB) can be temporally opened with focused ultrasound, and systemically injected 
AAV encoding a cell-specific-promoter-driven designer receptor accumulate in the treated 
area. After several weeks, the receptor is expressed in specific cells of the targeted area and 
targeted cells can be excited or inhibited by the designer chemogenetic drugs of the receptor. 
In a mouse model of memory formation, they show the ATAC could activate or inhibit 
neurons within the hippocampus, with selective control over individual brain regions. 
1.2 Significances and Innovations of the Thesis 
1.2.1 Significances 
The thesis study of ultrasound-guided gene delivery is of great significances in the 
following aspects: 
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(A) Meet unmet need for the gene therapy of atherosclerosis 
Cardiovascular disease is one of the leading causes of death globally, among which 
68% is attributed to atherosclerosis[101]. Atherosclerosis a chronic inflammatory process of 
the arterial wall that typically occurs at sites with disturbed blood flow (d-flow), such as 
curved and branched in in the vasculature. Disturbed blood flow generates shear stress on 
vascular endothelial cells, upregulating proatherogenic genes and downregulating 
atheroprotective genes. The dysfunctional endothelial cells initiates and perpetuates the 
plaque by recruiting monocytes from circulating blood. Therefore, normalizing 
dysfunctional endothelial cells by durable transgene expression of atheroprotective genes 
is a promising strategy for preventing and therapy of atherosclerosis. However, primary 
arterial endothelial cell is one of the most hard-to-transfect cell types that only a few 
attempts succeeded via invasive surgeries [102-104]. Therefore, this thesis meets the critical 
unmet need for the gene therapy of atherosclerosis by providing two methods for the gene 
therapy of atherosclerosis. 
(B) Providing an alternative method for the atherosclerotic therapy based on 
secreted protein 
Proteins have been developed as drugs for decades. However, proteins are 
intrinsically unstable and their circulating time is very short after system injection. To 
produce durable effect, repeated injection is needed. This thesis provided an alternative 
method for the delivery of secreted protein for the atherosclerotic therapy. After 
intramuscular injection of microbubbles and naked plasmid, the ultrasound is applied to 
the injecting site. The gene expression of the plasmid in skeletal muscle can be increased 
by over 10 fold compared with the naked plasmid injection. By manipulating the encoding 
sequence of the plasmid, proteins expressed in skeletal muscle can be secreted into blood 
and act on the targeted tissue for the atherosclerotic therapy. With this method, the 
transgene expression in skeletal muscle can persist for over 3 weeks after just one injection. 
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This method might also be applicable for other secreted proteins, such as ApoE[88, 89], IL-
12[105],  etc. 
(C) Providing a method for manipulating transgene expression in artery wall 
Blood vessels controls the blood supply to the body. Problems in any part of this 
big networks can cause disability or death. The most common vascular diseases include 
carotid artery disease (CAD), peripheral artery disease (PAD), abdominal aortic aneurysm 
(AAA), deep vein thrombosis (DVT) , arteriovenous malformation (AVM), etc. In the 
process of these disease, several cells (endothelial cells, smooth muscle cells, immunocytes, 
etc.) are involved through several complicated signal pathways. Although in vitro models 
are important for clarifying the underlying mechanisms of these diseases, in vitro 
conditions cannot replicate the in vivo conditions. Therefore, selectively increasing or 
inhibiting the expression of the gene of interested in the diseased vessels in vivo would be 
provide a strong evidence to demonstrate the role of the genes in the development of the 
vascular diseases. In this thesis, a simple but effected method for non-invasive image-
guided gene delivery to artery cells was established. Although the applicability of this 
technique is only demonstrated in carotid artery, abdominal aorta, and femoral artery, in 
theory, this technique might also be applicable for targeted gene delivery of almost all the 
vessels that can be visualized by ultrasound imaging. With considerable further 
improvement and validation, this technique will find its broad applications in the 
fundamental research and clinical translation in respect to vascular diseases.  
1.2.2 Innovations 
(A) For the first time, the transgene expression of KLK10 in skeletal muscle is 
achieved to inhibit atherosclerosis 
KLK10 is newly-discovered mechano-sensitive gene. KLK10 expression in 
endothelial cells is reduced by d-flow, resulting in reduction of endothelial inflammation, 
barrier disruption and atherogenesis. Our previous results also show that systematic 
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administration of recombinant KLK10 protein could inhibit atherosclerosis. However, 
recombinant protein have a very short circulation time and repeated injection is needed. In 
this research, ultrasound-enhanced transgene expression of KLK10 can be induced in 
skeletal muscle and thereby continuously produce KLK10 protein, which can be secreted 
into blood and act on the endothelium that is prone to atherosclerosis. With this method, 
the transgene expression of KLK10 in the skeletal muscle can last for over 3 weeks. 
(B) For the first time, the transgene expression in artery way can be manipulated 
in a noninvasive image-guided way 
By far, expressing external gene in selected arterial endothelial cell is a very hard 
task, while a few invasive methods can make it. In this research, we established a 
noninvasive image-guided method using ultrasound combined with microbubbles to 
selectively induce transgene expression in arterial endothelium, which has not been 
achieved before. The method established here utilizes the sonoporation effect by ultrasound 
and microbubbles to specifically express external genes in arterial endothelium. The gene 
expression in ultrasound-treated areas is as high as 86-fold higher than that in areas without 
ultrasound treatment, which is hard-to-achieve with conventional method. In addition, this 
method of gene delivery is image-guided. So genes can be delivered with this technology 
to almost all the area that can be in visualized by ultrasound imaging, including carotid, 
aorta, femoral artery, etc. 
(C) For the first time, targeted transgene expression of KLK10 in the arterial 
endothelium is achieved to inhibit atherosclerosis 
Although our previous research have demonstrated that the KLK10 expression is 
reduced by d-flow in vivo and might be an atheroprotective gene according to the in vitro 
experiments, there is still no direct evidence to confirm if local enhancement of KLK10 
expression in artery endothelium affected by d-flow in vivo can inhibit atherosclerosis. 
With the technique established here, targeted transgene expression of KLK10 in the artery 
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endothelium was induced in a noninvasive image-guided way. The transgene expression 
of KLK10 was demonstrated to significantly inhibit atherosclerotic development in the 
partial carotid ligation animal model. These results not only confirm the atheroprotective 
function of KLK10, but also provide an effective way to gene delivery of KLK10 in vivo 
for gene therapy of atherosclerosis. 
1.3 Thesis Organization 
This thesis contains 5 chapters in total. Chapter 1 and Chapter 5 are the introduction 
and conclusion, respectively. Chapter 2 to 4 are the main parts of this research and each 
part is organized by four sections: introduction, methods, results and discussions, and 
summary. The thesis is organized as follows: (1) In Chapter 1, a brief introduction of 
background knowledge was given, including the biology of atherosclerosis, KLK10 as a 
novel mechanosensitive gene, current targeting strategies for atherosclerosis, ultrasound 
for the therapy and diagnosis of atherosclerosis, skeletal muscular gene delivery, and AAV 
as an gene vector. After that, the significance and innovations of this research is 
summarized. (2) In the Chapter 2, the ultrasound-enhance transgene expression of KLK10 
in skeletal muscle was established to inhibited atherosclerosis. Firstly, the parameters 
involved in the ultrasound treatment is optimized. Then an atherosclerotic study is 
conducted to determine if the transgene expression of KLK10 skeletal muscle can inhibit 
atherosclerosis in the partial carotid ligation model. (3) In Chapter 3, the ultrasound-
imaging-guided method for targeted gene delivery to mouse artery was established. The 
parameters involved in this procedure is optimized, including ultrasound power, dose of 
microbubbles, and the time interval between microbubbles and AAV injection. The 
persistence of gene expression in both endothelium and media and adventitia layer were 
also characterized. The mechanism of enhanced gene expression by ultrasound was then 
studied. The permeability changes of carotid artery after ultrasound treatment was 
evaluated with Evans blue staining. The distribution of AAV in the artery wall was then 
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evaluated by labelling AAV with fluorescent dyes. This ultrasound-guided method of gene 
delivery was further expanded to other arteries besides carotid artery. Two important 
arteries were selected: abdominal aorta and femoral artery. (4) In Chapter 4, the ultrasound-
guided method of gene delivery was used for targeted gene delivery of KLK10. Firstly, the 
dose of KLK10-encoding AAV was optimized. Then the role of ultrasound, microbubbles 
and AAV were demonstrated. Finally, the transgene expression of KLK10 by the 
ultrasound-guided method were demonstrated to be able to inhibit atherosclerotic 




CHAPTER 2. ULTRASOUND-ENHANCED TRANSGENGE 
EXPRESSION IN SKELETAL MUSCLE 
2.1 Introduction 
 KLK10 is novel atheroprotective gene identified recently in our lab. Our previous 
results have shown that intravenous injection of recombinant KLK10 protein could inhibit 
atherosclerosis. However, recombinant protein has a very short circulation time and 
repeated injection is needed to get prolonged efficacy. Besides its traditional functions, 
skeletal muscle has been discovered to be an endocrine organ, secreting a lot of myokines 
to act on several organs[86]. Therefore, the use of highly vascularized muscle as an 
endocrine organ for the systemic administration of therapeutic proteins is a really 
interesting application. However, the efficacy of gene transfer in skeletal muscle through 
direct intramuscular injection of naked plasmid is very limited. The sonoporation effect 
generated by microbubble destruction with ultrasound have been demonstrated to be able 
to increase transgene expression in skeletal muscle[90]. Therefore, we hypothesized that 
ultrasound in combination with microbubbles could increase the transgene expression of 
KLK10 in skeletal muscle and thus inhibit atherosclerotic development. 
Figure 2.1 Ultrasound-enhanced transgene expression of KLK10 in skeletal muscle to 
inhibit atherosclerosis. 
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 In this chapter, we will firstly optimize the parameters of ultrasound treatment, 
including duty, burst rate, power, time, etc. The optimized parameters will then be used for 
transgene expression of KLK10 in skeletal muscle to determine if the atherosclerosis can 
be inhibited in the partial carotid ligation model. 
2.2 Methods 
2.2.1 Microbubble preparation 
 The microbubbles are prepared with a modified mechanical agitation method 
established in our lab. The method is described as followings: 
a) Dissolve DSPC and DSPE-PEG2000 in ethanol at the concentration of 10 mM. 
b) Add 1800 μL DSPC and 200 μL DSPE-PEG2000 solution into a 20 mL glass vial and 
mix. 
c) Heat the glass vial at 80 ℃ and evaporate the ethanol completely under nitrogen gas 
flow. 
d) Add 1 mL (1.036g) propylene glycol and heat at 60 ℃ to fully dissolve the lipids. 
e) Add 1.26 g glycerol to the solution. 
f) Place a magnetic stir bar into the glass vial. Heat the vial at 60 ℃ and make sure the 
solution is clear and no precipitates exist. 
g) Under vigorous stirring, add 8 mL PBS (pre-warmed at 60 ℃) to the lipid solution. 
h) Filter the solution with a 0.45 μm syringe filter and then 0.22 μm syringe filter to sterilize 
the solution. 
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i) Sub-pack the solution into 2-mL glass vials (1 ml/vial). The headspace of the vial is filled 
with perfluoropropane gas. The solution can be stably stored at 4 ℃ for several months. 
j) Before use, the vial is shaken with the Vialmix for 45s to get the microbubbles. 
k) The concentration of microbubbles can be quantified with cytometry. The concentration 
of microbubbles is around 1.2×1010/mL. 
2.2.2 Plasmid construction 
Figure 2.2 Structure of the plasmids. 
 The plasmid was constructed by GENEWIZ (Suzhou, China) and confirmed with 
DNA sequencing. Four plasmids were involved in this research (Figure 2.2). The plasmid 
pCMV-Luc was obtained from Ambion. The plasmid was constructed by adding an Igκ 
signal peptide sequence to the N-terminal of the sequence of luciferase. The pCMV- 
KLK10-T2A-Luci was constructed by adding cDNA sequence of KLK10 and T2A peptide 
sequence to the N-terminal of the sequence of luciferase. The pCMV- Igκ-KLK10-T2A-
Luci was further constructed by adding the Igκ signal peptide sequence to the N-terminal 
of the sequence of KLK10. 
2.2.3 Protocols for gene transfer in skeletal muscle 
 The equipment used for the ultrasound treatment is the Sonopore KTAC-4000 
sonoporator equipped with an S-PW-1.0-20mm probe (Plane Wave Transducer, 20mm 
diameter tip, 1MHz). 
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1) Anesthetize the mice with isoflurane in oxygen in an anesthesia chamber. Maintain body 
temperature using the heating pad. Ensure complete anesthetization by assessing for a 
reaction to a toe pinch, and then maintain anesthesia at 1.5 - 2% isoflurane. 
2) The animal was shaved to remove any fur from both thighs. Wipe the site of hair removal 
and surrounding area down with an alcohol prep pad. 
3) Dilute the microbubbles with pure water to a concentration of 5×108/mL.  
NOTE：Microbubbles are not very stable after dilution. Do not leave microbubbles 
exposed to the air for longer than 30 min. It’s better to dilute the microbubbles every time 
before use. 
4) Add 2 μL 9% sodium chloride solution, 1μL diluted microbubble solution and 50 μg 
plasmid to 200-μL conical tube. Then add some water to make the total volume to be 20 
μL. 
5) Mix the solution well and inject the solution intramuscularly into the thigh muscle with 
a 30G syringe. 
6) Place the probe on the top of the inject site and use some ultrasound gel to couple the 
probe with the mouse thigh. 
7) Turn on the sonoporator to apply the ultrasound (Frequency: 1MHz, Duty cycle: 25%, 
Burst rate: 50Hz, Intensity: 1.5W/cm2, Wave Pattern Type: sine, Time: 4 min,) 
2.2.4 Protocols for bioluminescence imaging 
1) Thaw D-Luciferin Potassium Salt at room temperature and dissolve in PBS (no calcium 
or magnesium) to a final concentration of 15mg/mL. 
2) Sterilize the Luciferin solution through a 0.22μm syringe filter. 
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3) Once prepared, the solution need to be used immediately or stored in -20℃ after sub-
packed. 
4) For bioluminescence imaging in vivo, anesthetize the mice with isoflurane in oxygen. 
The animal is then shaved to remove any fur on the hind leg. 
5) Intraperitoneally inject with 10μL of Luciferin stock solution per gram of body weight 
(~200 μL/mouse). 
6) The bioluminescence images are then collected at 12 min post injection with an exposure 
time of 2 minutes. 
2.2.5 Mouse partial carotid ligation surgery 
 All animal experiments were approved by the Animal Care and Use Committee at 
Peking University. The partial carotid ligation surgery was conducted as previously 
reported[17]. Male C57BL/6 and ApoE-/- mice (Charles River Laboratories, Beijing) were 
allowed ad libitum to standard chow diet and water until surgery at 8–9 weeks of age. Mice 
were anaesthetized with 3.5% isoflurane initially and then ~2% during the entire procedure. 
Before surgery, analgesic carprofen (5mg/kg) was administrated subcutaneously. The LCA 
bifurcation was exposed by blunt dissection and three caudal branches of LCA (left 
external carotid, internal carotid and occipital arteries) were ligated with 6-0 silk sutures 
while leaving the superior thyroid artery intact. For atherosclerotic studies, the ApoE-/- 
mice were fed with a Paigen’s high fat diet (Research diets) following the surgery until 
killed. C57BL/6 mice were continued with a chow diet. 
2.2.6 Plaque lesion analysis 
 Carotid arteries were isolated en bloc from ligated ApoE-/- mice fed with a high fat 
diet for 3 weeks. The artery trees were photographed using a dissection microscope and the 
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opaque area covered by plaque and total area of LCA were quantified using NIH ImageJ 
software 
2.2.7 Immunohistochemistry 
 Arteries were embedded in optimal cutting temperature compound (Tissue-Tek), 
frozen on dry ice and stored at -80 ℃ until used. To visualize atherosclerosis development, 
Oil-red-O staining was carried out. Frozen sections were fixed in formalin for 10 min, 
rinsed with water and 60% propylene glycol, and then stained with Oil Red O staining 
solution (Solarbio). Slides were then differentiated in 60% propylene glycol, rinsed with 
distilled water, and counterstaining was done using Mayer’s haematoxylin (Beijing 
Leagene Biotechnology Co., Ltd.) for 5 min. 
2.3 Results and discussions 
2.3.1 Multi-parameter optimization of transgene expression in skeletal muscle 
 Gene transfer for gene therapy is a rapidly expanding field. Tissues with high 
transgene efficacy is sought including tumors, and organs such as the liver, heart, or brain. 
Special interest has been devoted to gene delivery to skeletal muscle fibers, for the 
correction of myopathies, local secretion of angiogenic or neurotrophic factors, and 
vaccination. Although transgene expression in skeletal muscle can be achieved by 
intramuscular injection of naked plasmid, the expression is usually very weak and 
inconsistent. Therefore, a lot of researches have been done to increase the level and 
reliabilities of skeletal muscular gene expression. Ultrasound destruction by high power 
ultrasound can increase the permeability of cells and thereby enhance the transgene 
expression. Therefore, we focused on enhancing gene transfer to skeletal muscle utilizing 
the sonoporation effect. 
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 Galina Shapiro et al. used nonlinear ultrasound and bioluminescence imaging to 
optimize the acoustic pressure, microbubble concentration, treatment duration, DNA 
dosage, and number of treatments required for in vivo luciferase gene expression in a 
mouse thigh muscle model[90]. Mice injected with 50 μg luciferase plasmid DNA and 5 × 
105 microbubbles followed by ultrasound treatment at 1.4 MHz, 200 kPa, 100-cycle pulse 
length, and 540 Hz pulse repetition frequency (PRF) for 2 min exhibited superior transgene 
expression compared to all other treatment groups.  
Figure 2.3 Luciferase expression profile in mice treated with microbubble-enhanced 
sonoporation at various ultrasound power. n=4, data are shown as mean ±SD. 
 In this research, we modified the protocol used by Galina Shapiro et al. The 
Sonopore KTAC-4000 sonoporator equipped with an S-PW-1.0-20mm probe (Plane Wave 
Transducer, 20mm diameter tip, 1MHz) was used in our research. 50 μg luciferase plasmid 
DNA (pCMV-Luc) and 5 × 105 microbubbles were dispersed in saline and intramuscularly 
injected into thigh muscle of the mice followed by ultrasound treatment. The parameters 
of the ultrasound treatment were firstly optimized 
The power of ultrasound was firstly optimized. Mice were injected with 50 μg plasmid 
DNA premixed with 5 × 105 microbubbles and then treated with a duty of 50%, a burst rate 
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of 50 Hz, and a power of 0.5 W/cm2, 1 W/cm2, 1.5 W/cm2, and 2 W/cm2 for 4 min. Gene 
expression of luciferase was monitored using the bioluminescence imaging for 8days after 
treatment. As shown in Figure 2.3, at day 4, day 6, and day 8, the highest gene expression 
was found at the power of 1.5 W/cm2. Therefore, the power of 1.5 W/cm2 was selected for 
further experiments. 
 The duty is defined as the fraction of time the ultrasound field is “on”. Mice were 
injected with 50 μg plasmid DNA premixed with 5 × 105 microbubbles and then treated 
with a burst rate of 50 Hz, a power of 1 W/cm2, and with a duty of 25%, 50%, 75%, and 
100%for 4 min Gene expression of luciferase was monitored using the bioluminescence 
imaging for 8days after treatment. As shown in Figure 2.4, the transgene expression is 
negatively related to the duty. The highest transgene expression is found with a duty of 
25%. 
Figure 2.4 Luciferase expression profile in mice treated with microbubble-enhanced 
sonoporation at various duties. n=4, data are shown as mean ±SD. 
 Burst rate is the frequency with which the pulses are repeated. Mice were injected 
with 50 μg plasmid DNA premixed with 5 × 105 microbubbles and then treated, a duty of 
50%, a power of 1 W/cm2, and with a burst rate of 25 Hz, 50 Hz, 75 Hz, and 100 Hz for 4 
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min Gene expression of luciferase was monitored using the bioluminescence imaging for 
8 days after treatment. As shown in Figure 2.5, the transgene expression of luciferase is 
not significant changed with the burst rate. 
Figure 2.5 Luciferase expression profile in mice treated with microbubble-enhanced 
sonoporation at various burst rates. n=4, data are shown as mean ±SD. 
Figure 2.6 Luciferase expression profile in mice treated with microbubble-enhanced 
sonoporation at various treatment time. n=4, data are shown as mean ±SD. 
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 Finally, the total treatment times is optimized. Mice were injected with 50 μg 
plasmid DNA premixed with 5 × 105 microbubbles and then treated, a duty of 50%, a power 
of 1 W/cm2, and with a burst rate of 50 Hz for 4 min Gene expression of luciferase was 
monitored using the bioluminescence imaging for 8days after treatment. As shown in 
Figure 2.6, the transgene expression with a treatment time of 1 min, 2min and 4 min are 
not significantly different, while the expressing is much reduced when the treatment time 
is as high as 6 min. 
2.3.2 Combining effect of ultrasound and microbubbles for gene delivery 
Figure 2.7 Luciferase expression profile in mice with different treatments. n=4, data are 
shown as mean ±SD. 
Figure 2.8 Representative bioluminescence images of the thigh leg of mice with different 
treatments at the 21st day.  
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 Based on the previous results, the ultrasound with a duty of 25%, a power of 1.5 
W/cm2, and with a burst rate of 50 Hz for 2 min was selected for further experiments. To 
clarify the combining effect of ultrasound and microbubbles in enhancing transgene 
expression in skeletal muscle, the mice were divided into four groups for four different 
treatments: DNA+MB+US (plasmid and microbubbles injection followed by ultrasound 
treatment), DNA+MB (plasmid and microbubbles injection only), DNA+US (plasmid 
injection followed by ultrasound treatment), and DNA (plasmid injection only).The gene 
expression were determined by bioluminescence imaging for 21 days post treatment.  As 
shown in Figure 2.7&2.8, microbubble or ultrasound alone did not induce any significant 
changes of transgene expression as compared with naked plasmid injection. However, 
ultrasound in combination with microbubbles can induce over 10-fold increase in transgene 
expression compared with all the other groups. This demonstrated that the microbubble-
enhanced sonoporation can significantly enhance transgene expression in skeletal muscle. 
 Transgene expression induced by the combining treatment of microbubbles and 
ultrasound could persist as long as 3 weeks (longer time was not determined). This is one 
of biggest advantages of gene delivery as compared with protein delivery. Since the 
circulation time of proteins is very short, repeated injection is needed. With the method 
established here, transgene expression in skeletal muscle can persist for a long time with 
just one injection. 
2.3.3 KLK10 expression in skeletal muscle to inhibit atherosclerosis 
 The ultrasound-enhanced transgene expression in skeletal muscle was further 
applied for KLK10 delivery to determine if this method can be used to inhibit 
atherosclerosis. KLK10 is novel atheroprotective gene identified recently in our lab. Our 
previous results have shown that intravenous injection of recombinant KLK10 protein 
could inhibit atherosclerosis. However, recombinant protein has a very short circulation 
time and repeated injection is needed to get prolonged efficacy. The ultrasound-enhanced 
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transgene expression of KLK10 is expect to continuously produce KLK10 protein in 
skeletal muscle, which can be secreted into blood and inhibit atherosclerosis. 
Figure 2.9 Experimental design to determine if KLK10 expression in skeletal muscle can 
inhibit atherosclerosis. 
 To monitor the expression of KLK10 in the skeletal muscle, the KLK10 sequence 
is linked with the luciferase sequence through a T2A pepetide. The T2A peptide is a “self-
cleaving” peptide, which undergoes self-cleavage to generate mature proteins by a 
translational effect that is known as “stop-go” or “stop-carry”[106-108]. The cleavage site is 
located between the last glycine of its C-terminal and the first praline of the downstream 
protein. The incorporation of T2A makes the genes co-expressed while their function are 
not affected. Therefore, the level of luciferase expression should reflect how much KLK10 
is the result of exogenous expression. In this way, the KLK10 expression can be determined 
by the bioluminescence imaging. In addition, to make the KLK10 secreted out of the cells, 
an Igκ signal peptide is also added to the N-terminal of the KLK10 sequence. The Igκ 
signal peptide mediates targeting of KLK10 to the endoplasmic reticulum (ER), so that 
KLK10 can be efficiently secreted. Therefore, the resultant pCMV- Igκ-KLK10-T2A-Luci 
plasmid is used for the in vivo delivery of KLK10. In addition, the plasmid pCMV-Igκ-
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Luci which lacks of KLK10 sequence and plasmid pCMV-KLK10-T2A-Luci whick lacks 
of Igκ signal peptide were also constructed as control. 
Figure 2.10 Bioluminescence images of the mice at different time points. 
 The mice were divided into four groups (Figure 2.9). The Control group was the 
group without any treatment at Day -2 and Day 5. The Luci group, W/O Igκ group, and 
KLK10 group were intramuscularly injected with pCMV-Igκ-Luci, pCMV-KLK10-T2A-
Luci, and pCMV- Igκ-KLK10-T2A-Luci premixed with microbubbles followed by 
ultrasound treatment in both legs, at Day -2 and Day 5, respectively. The mice were 
subjected to partial carotid ligation at Day 0 and then fed with high fat diet for three weeks. 
 Utilizing the sequence of luciferase inserted in the plasmids, the transgene 
expression can be monitored noninvasively with the bioluminescence imaging. As shown 
in Figure 2.10, no signal is detected in the Control group owing to lack of luciferase 
expression. The luciferase are expressed in both legs of the other three groups, indicating 
that the transgenes encoded by the plasmids were expressed in the skeletal muscle. 
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Although there are some variations in the gene expression， there are no significant 
difference between these three groups.  
Figure 2.11 Atherosclerotic plaque analysis. (A) Three weeks post the partial carotid 
ligation surgery, the mice were sacrificed and the artery trees were dissected out for bright 
field imaging. (A) The percentage of atherosclerotic lesion in LCA is quantified with Image 
J. Data shown as mean ± s.e.m.; *p<0.05, ns p>0.05 as determined by student’s t-test.  
 The mice were sacrificed at the 21st day for atherosclerotic plaque analysis. As 
shown in Figure 2.11, the plaque lesions in the Luci group and W/O Igκ group were not 
significantly different from that in the Control group, while the plaque lesions in the 
KLK10 group were significantly different from that in the Control group. Compared with 
the Luci group, the plaque lesion area in KLK10 group is decreased from 64.6% to 18.0%. 
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 The carotid arteries in the Luci and KLK10 group were also sectioned and stained 
with Oil-Red-O (Figure 2.12). The plaque size in KLK10 group is reduce by 77.4%. These 
results demonstrated that the transgene expression of KLK10 in skeletal muscle could 
inhibit atherosclerosis. 
Figure 2.12 Oil-Red-O staining. (A) The carotid arteries in the Luci and KLK10 group 
were further sectioned and stained with Oil-Red-O. (B) The plaque size indicated by the 
Oil-Red-O staining were quantified. Data shown as mean ± s.e.m.; *p<0.05, as determined 
by student’s t-test. Note: The mice used for the Oil-Red-O staining is different from the 
mice in Figure 2.12. This atherosclerotic experiments were repeated in two batches of mice. 
2.4 Summary 
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 In this chapter, we established a method to induce transgene expression of KLK10 
in skeletal muscle to inhibit atherosclerosis. After intramuscular injection of naked plasmid 
and microbubbles, ultrasound is applied to the injection site to induced increased transgene 
expression in the skeletal muscle. After optimizing the ultrasound parameters, the 
ultrasound-enhanced transgene expression in skeletal muscle is increased by over 10 fold 
compared with naked plasmid injection and can persist for over 3 weeks. By adding a signal 
peptide to the N-terminal of coding sequence of KLK10, the expressed KLK10 proteins 
can be secreted out, enter into the blood, and act on the inflamed area to inhibit 
atherosclerosis. The transgene expression of KLK10 in skeletal muscle reduced the 
atherosclerotic lesions from 64.6% to 18.0% in the partial carotid ligation model. These 
results demonstrated the ultrasound-enhanced transgene expression of KLK10 in skeletal 






CHAPTER 3. ULTRASOUND IMAGING-GUIDED GENE 
DELIVERY TO MOUSE ARTERY  
3.1 Introduction 
 In the previous chapter, ultrasound combined with microbubbles was demonstrated 
to be able to increase transgene expression in skeletal muscle. The ultrasound-enhanced 
transgene expression of KLK10 in skeletal muscle could significantly inhibit 
atherosclerosis in the partial carotid ligation model. However, this kind of technology is 
only suitable for the gene delivery of secreted proteins and proteins expressed in skeletal 
muscle will also act on all the major organs in addition to artery. Therefore, there is a need 
to establish a new method for targeted delivery exogenous genes to artery endothelium.  
Figure 3.1 Schematic illustration the proposed rationale of ultrasound imaging-guided gene 
delivery. 
 In this chapter, a simple but effective method for image-guided targeted gene 
delivery to is established based on the sonoporation effect by ultrasound and microbubbles 
(Figure 3.1). Under the ultrasound imaging, the carotid artery can be clearly visualized. 
The area of interest can be selected from the ultrasound image. Then microbubbles can be 
injected intravenously. After that, ultrasound will be applied with the imaging probe to the 
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selected area. Hopefully, the permeability of arterial endothelium will increase and then 
AAV gene vectors encoding genes of interest will be injected. The gene is expected to be 
selectively expressed in the ultrasound-treated area. In this chapter, various parameters 
involved in this procedure will be optimized, including, microbubble concentration, 
ultrasound power, the time interval between microbubble and AAV injection, etc. Some 
characterization of the procedure will also be conducted, including specificity, durance, 
safety, etc. To explain the reason why ultrasound in combination with microbubble and 
AAV can enhance transgene expression in artery, Evans blue staining will be used and then 
AAV will be labelled with fluorescent dyes to track the distribution of AAV in arterial wall. 
Finally, the ultrasound-guided method for targeted gene delivery to artery will be further 
demonstrated for the potential applications in the targeted gene delivery to abdominal aorta 
and femoral artery. 





3.2.1 AAV packaging  
 Recombinant AAV serotype-9 expressing EGFP under the control of CAG 
promoter, a hybrid construct consisting of the cytomegalovirus (CMV) enhancer fused to 
the chicken beta-actin promoter are produced by Vigene Biosciences (Jinan, China) (Figure 
3.1).  
3.2.2 Isolation of Endothelial-Enriched RNA.  
Figure 3.3 Marker genes (PECAM-1 and α-SMA) expression of endothelial-enriched RNA 
samples from LCA and RCA. 
 Endothelial-enriched RNA from the carotid arteries was extracted as previously 
described[17]. Briefly, mice were killed by CO2 inhalation and perfused with saline via the 
left ventricle after severing the inferior vena cava. The left common carotid artery (LCA) 
and the right common carotid artery (RCA) were then isolated and carefully cleaned. The 
carotid lumen was quickly flushed with 100 μl of QIAzol lysis reagent (QIAGEN) using a 
29-gauge insulin syringe in a microfuge tube. The eluate was then used for intimal RNA 
isolation using an RNA MiniPrep kit (ZYMO research) according to the manufacturer’s 
instructions. The carotid artery leftover after flushing with QIAzol was used to prepare 
RNA from media and adventitia. Media and adventitia was placed in QIAzol lysis reagent 
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(350 μl per carotid), and homogenized with a homoginizer. Marker genes (PECAM-1 and 
α-SMA) was used to determine the purity of endothelial RNA in each prep (Figure 3.3). 
3.2.3 Quantitative Real-Time PCR (qPCR).  
 RNA samples were reverse-transcribed with the PrimeScript RT reagent kit 
(TAKARA) and qPCR was performed on selected genes using the SYBR Premix Ex Taq 
(TAKARA) with custom-designed primers using 18S as house-keeping control. The Bio-
rad CFX96 Touch qPCR machine was used for qPCR measurements. The PCR conditions 
were 30 s at 95 ℃, followed by 40 cycles of 95 ℃ for 5 s and 60 ℃ for 30 s. Fold changes 
between LCA and RCA were determined for all targets using the ΔΔCt method. Sequences 


















3.2.4 General procedures for ultrasound-guided gene delivery to carotid 
Figure 3.4 General procedures of ultrasound treatment of carotid artery 
 All ultrasound imaging treatments were conducted using a DC-8 ultrasound system 
equipped with a L12-3E linear-array probe (Mindray). Mice were anesthetized with inhaled 
isoflurane, and body temperature was maintained on a heated stage for the duration of 
studies. The position of left carotid artery can be found under B-mode ultrasound imaging 
(Figure 3.4). Then switch to colour Doppler-mode. Change the size and position of colour 
box to the region of interest, zoom to the selected area and then change mechanical index 
(MI) to desired value (0.2, 0.3, 0.4, and 0.5, respectively). Immediately after microbubbles 
injection, press the “Freeze” button every 0.5 s so that ultrasound is applied in an ON/OFF 
mode (0.5s ON followed by 0.5s OFF) for a total time of 30s. After the ultrasound treatment, 
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the AAV encoding gene of interest will be injected intravenously. At certain time point 
post the treatment, the mice are sacrifice for further characterization of gene expression. 
3.2.5 En face staining of carotid artery 
 The carotid arteries are excised, fixed in 4% paraformaldehyde, penetrated with 
0.025% Triton X-100 for 10 min, blocked with 10% goat serum for 1 h at room temperature, 
and incubated with primary anti-EGFP antibodies (abcam ab6556) overnight at 4 ℃. To 
visualize primary antibodies, Alexa Fluor ® 594-conjugated secondary antibody (abcam 
ab150080) was used for 1 h at room temperature. Nuclei were counterstained with DAPI. 
Samples were imaged using a Nikon confocal microscope. 
3.2.6 Evaluate the permeability changes of carotid artery with Evans blue 
 The permeability changes of the artery can be determined by Evans blue. At pre-
determined time points post ultrasound treatment, inject 100 μL Evans blue (1% in saline) 
intravenously and sacrifice the mouse 30 min later. The carotid arteries are then dissected 
and observed under microscope. The level of blue colour in the treated area directly reveals 
the permeability changes by ultrasound treatment.  
3.2.7 Fluorescence labelling of AAV 
Figure 3.5 Paradigm of fluorescence labelling of AAV. 
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 The AAV was modified with fluorescent dyes following a procedure reported in 
the literature with some modification (Figure 3.5)[109]. In brief, purified AAV9 was 
incubated for 1 hour at 4 ℃ in PBS with tenfold excess of Sulfo-Cyanine3 NHS ester over 
the capsid protein units (each AAV is composed of 60 capsid protein units). Labelled 
viruses AAV-Cy3 were separated from the free dyes by dialysis against PBS at 4 ℃ and 
stored at −80 ℃ in small aliquots. 
3.2.8 Fluorescence tracking of AAV in carotid artery 
 Following ultrasound treatment to LCA, 5×1011 vg/mouse AAV-Cy3 was injected 
intravenously. At predetermined time points post injection, the mice were sacrificed. The 
carotid arteries were dissected, fixed with formalin, and stained with DAPI. Samples were 
then subjected to en face confocal imaging with a Nikon confocal microscope. 
3.2.9 General protocols for ultrasound treatment of abdominal aorta 
 All ultrasound imaging treatments were conducted using a DC-8 ultrasound system 
equipped with a L12-3E linear-array probe (Mindray). Mice were anesthetized with inhaled 
isoflurane, and body temperature was maintained on a heated stage for the duration of 
studies. The mice were placed supine and shaved to expose the abdomen. The ultrasound 
probe was placed in parallel with the abdominal aorta. The position of abdominal aorta can 
be found under B-mode ultrasound imaging. Then switch to colour Doppler-mode. Change 
the size and position of colour box to the region of interest, zoom to the selected area and 
then change mechanical index (MI) to 0.4. Immediately after microbubbles injection 
(3×107/mouse), press the “Freeze” button every 0.5 s so that ultrasound is applied in an 
ON/OFF mode (0.5s ON followed by 0.5s OFF) for a total time of 1 min. After the 
ultrasound treatment, the AAV encoding gene of interest will be injected intravenously. At 
certain time points post the treatment, the mice are sacrifice for further characterization of 
gene expression. 
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3.2.10 General protocols for ultrasound treatment of femoral artery 
 Mice were anesthetized with inhaled isoflurane, and body temperature was 
maintained on a heated stage for the duration of studies. The mice were placed prone and 
shaved to expose the hind leg. The ultrasound probe was placed in parallel with the 
femoral artery. Switch the ultrasound imaging to the contrast mode. Inject microbubbles 
(1×108/mouse) and find the position of femoral artery under the contrast mode. Change 
the size and position of box to the region of interest, zoom to the selected area. Switch the 
ultrasound imaging to the colour Doppler mode and treat the selected area with a MI of 
0.4. Press the “Freeze” button every 0.5 s so that ultrasound is applied in an ON/OFF 
mode (0.5s ON followed by 0.5s OFF) for a total time of 30s. After the ultrasound 
treatment, the AAV encoding gene of interest will be injected intravenously. At certain 
time point post the treatment, the mice are sacrificed for further characterization of gene 
expression. 
3.3 Results and Discussion  
3.3.1 Optimization of the ultrasound power and microbubble dose 
 To do the ultrasound imaging-guided gene delivery, a DC-8 ultrasound system 
equipped with a L12-3E linear-array probe was used. This machine has already been used 
in clinic. The centre frequency of this probe is 4.4 MHz, which is used in clinic for carotid 
imaging. With this system, we can clearly see the blood flow in mouse carotid artery under 
the colour-Doppler mode (Figure 3.4). By changing the position and size of the colour box, 
the area of interest can be selected. Then zoom the image to the selected area so that 
ultrasound only irradiated to the selected area. After injecting the microbubbles, the 
permeability of the artery in selected area is expected to be increased by the ultrasound. 
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After that, the AAV9 vectors encoding EGFP is injected. Hopefully, the EGFP can be 
expressed in the area with ultrasound treatment. 
Figure 3.6 Experiment design for optimization of the ultrasound power and microbubble 
dose. 
Figure 3.7 EGFP expression in carotid endothelium after different treatments. LCA is 
treated with ultrasound while RCA is used as control. n = 3 or 4 mice each, data shown as 
mean ± s.e.m. 
 During this process, the dose of microbubbles and the power of ultrasound are the 
two key factors that may affect the transgene expression (Figure 3.6). Two microbubble 
doses were chosen: 3×107/mouse (~1.5×109/kg) is the lowest dose that may cause 
significant artery permeability changes according to our pilot experiments, while 1×
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108/mouse (~5×109/kg) is close to the highest dose that will not cause significant 
shadowing effect when doing ultrasound imaging of mouse carotid. Four ultrasound power 
were selected with the mechanical index (MI) at 0.2, 0.3, 0.4, and 0.5, respectively. 
 In this experiment, the ultrasound is applied to left common carotid artery (LCA), 
while the right common carotid artery (RCA) is used as the control. The mice were 
sacrificed at day 4 to check gene expression in carotid endothelium with qPCR. As shown 
in Figure 3.7, the gene expression in the LCA is positively related to the MI used for the 
treatment. At the same MI, increasing MB dose could increase the gene expression. In all 
the groups, the gene expression in RCA is very low. At the MB dose of 3×107/mouse, the 
gene expression in LCA is nearly linearly related to the MI. This could be explained by 
increasingly higher permeability with high ultrasound power. At the MB dose of 3×
107/mouse, the gene expression of MI=0.4 is not significantly different from that of MI=0.5. 
So based on this results, the MI=0.4 and MB dose at 1×108/mouse were selected for 
further experiments.  
 Under the optimized condition, the gene expression in the endothelium of LCA is 
about 24 times higher than that of RCA at the 4th day post ultrasound treatment. In this 
experiment, the gene expression in both RCA and LCA was determined by qPCR. However, 
limited by the amount of RNA that can be obtained from one mouse artery, the sample size 
is very small, which may result in accurate results obtained with qPCR. When the EGFP 
expression of RCA is determined with qPCR, the Ct value is close to 40, which is usually 
thought to be a result of nonspecific PCR reactions. Therefore, the EGFP expression in 
RCA is probably overestimated. It is reasonable to hypothesis that the gene expression the 
endothelium of LCA might be more than 24 times higher than that of RCA. With this high 
enhancement in transgene expression, the technology may have a lot of potential 
applications. 
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Figure 3.8 ICAM1 and VCAM1 expression in carotid endothelium after different 
treatments. LCA is treated with ultrasound while RCA is used as control. n = 3 or 4 mice 
each, data shown as mean ± s.e.m; ns, p>0.05 as determined by student’s t-test. 
 The microbubble destruction caused by high-power ultrasound can increase the 
permeability of the cells in the arterial wall. Although the efficacy of transgene expression 
is very high, the potential long-term damage to the cells need to be determined. Two key 
maker genes of inflammation, ICAM1 and VCAM1 were measured with all the samples. 
As shown in Figure 3.8, no significant difference in VCAM1 and ICAM1 expression were 
detected in all the groups. Since this result is just from the artery samples obtained from 
mouse at the 4th day post ultrasound treatment, we cannot rule out the possibility that the 
ultrasound treatment may cause some inflammation in the first three days. However, we 
can conclude that the ultrasound treatment does not cause a long-term inflammation in the 
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arterial endothelial cell. Therefore, this ultrasound-based gene delivery method is a 
relatively safe technology. 
 The gene expression in carotid was also characterized with immunofluorescence 
imaging. As shown in Figure 3.9, the EGFP is significantly highly expressed in the carotid 
endothelium of ultrasound-treated side, while almost no EGEP expression can be observed 
in the carotid without ultrasound treatment at the 4th day post ultrasound treatment. This 
results further confirmed the results of qPCR, since the gene expression in ultrasound-
treated area is over 20 times higher than that without ultrasound treatment. In addition, the 
EGFP expression was predominately in the endothelium, not the media or adventitia layer.  
Figure 3.9. Confocal images of en face staining of carotid artery. The mouse was sacrificed 
4 days post ultrasound treatment. The carotid arteries were dissected and stained with 
EGFP antibody and analysed by enface confocal imaging. RCA is the control side without 
ultrasound treatment, while LCA is the ultrasound-treated side. IEL: internal elastic lamina. 
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Figure 3.10 The size of ultrasound-treated area can be changed.  (A) The color box was 
changed to the top part of the carotid artery so that ultrasound is only applied to top part. 
(B) 4 days post ultrasound treatment and AAV9-EGFP injection, the mice were sacrificed, 
and the carotid arteries were dissected and stained with EGFP antibody for enface confocal 
imaging. The while box indicate the area with ultrasound treatment. 
 Since the transgene is only expressed in the ultrasound-treated area, the size of 
transgene expression is determined by the area of ultrasound treatment. With ultrasound 
imaging, the size of the color box can be changed from the ultrasound images so that areas 
with ultrasound treatment can be changed very easily. As shown Figure 3.10, the color box 
is adjusted to the top half of carotid and then inject the microbubbles to selectively treat 
the top part of carotid artery. The mouse was then injected with AAV9-EGFP and 
 55 
sacrificed four days later for en face immunofluorescence imaging. In the fluorescence 
images, the EGFP expression can only be detected in the top half of carotid, not in the 
bottom half. This experiment further demonstrated the high specificity of this ultrasound-
guided method of gene delivery. 
3.3.2 Optimizing the time interval between MB and AAV injection 
Figure 3.11 Experiment design for optimizing the time interval between MB and AAV 
injection. 
 The time interval between MB and AAV injection is another important parameter 
for the ultrasound imaging-guided gene delivery. Seven different time intervals were 
selected for this experiment: 0min (AAV co-injected with MB), 5min, 1 h, 3 h, 12 h, 24 h, 
and 48 h (Figure 3.11).  4 days post the AAV injection, the EGFP expression in the carotid 
endothelium was determined with qPCR. As shown in Figure 3.12, the gene expression 
with a time interval between 0min and 3 h didn’t shown any statistics difference. This 
indicates that the permeability changes induced by the sonoporation effect could last for at 
least 3 h. Gene expression with a time interval at 12 h was significant reduced compared 
with that at 5 min, indicating that the permeability was mostly recovered at that time. 
  In the literature, injecting gene vectors together with MB is a very common 
strategy [80, 82, 110, 111]. There are two proposed mechanisms for enhanced gene expression. 
On one hand, the enhanced permeability caused by the sonoporation effect between US 
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and MB can increase the accumulation of gene vectors. On the other hand, the power 
generated by the destruction of MBs can push the gene vectors into adjacent cells or tissues. 
Therefore, according to this theory, injecting gene vectors simultaneously with MB will be 
the optimal choice. However, according to the above experimental results, injecting the 
gene vectors before or after ultrasound treatment doesn’t make significant differences. 
Therefore, the former mechanism for enhanced gene may make the major contribution. 
However, injecting gene vectors together with MB is not always that convenient. Once 
injected, the gene vectors start to be cleared out from blood. If injecting gene vectors is 
ahead of ultrasound treatment, the time interval between these two steps should be as short 
as possible. Otherwise, the gene expression will decrease a lot, since the gene vectors can 
accumulate in the target sites only if the permeability has changed. Therefore, for the sake 
of experimental convenience, injecting gene vectors post ultrasound treatments is selected 
for the following experiments. 
Figure 3.12 EGFP expression in carotid endothelium after ultrasound treatments at 
different time intervals between MB and AAV injection. LCA is treated with ultrasound 
while RCA is used as control. n = 3 or 4 mice each, data shown as mean ± s.e.m. ns p > 
0.05, ***p < 0.001 as determined by Student's t-test. 
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3.3.3 Persistence of the gene expression 
Figure 3.13 Experiment design for evaluation of the persistence of gene expression 
 Compared with other therapies based on chemical drugs, proteins, RNA and so on, 
one of the biggest advantages of gene therapy is the durable effect with just one injection. 
The persistence of the gene expression induced by the ultrasound-based method was 
evaluated (Figure 3.13). After the ultrasound treatment and AAV9-EGFP injection, the 
mice were sacrificed at different time points (4 days, 9 days, 2 weeks, 4 weeks, and 8 
weeks). The gene expression in both endothelial cells (ECs) and media and adventitia 
(M+A) layer was determined.  
 As shown in Figure 3.14, the gene is highly expressed in ECs from 4 days to 8 
weeks. The highest gene expression is found at the 4th week. The gene in the ultrasound-
treated side is significantly higher than the untreated side. Interestingly, the gene is also 
expressed in M+A layer. However, the expression in M+A is not synchronized with ECs. 
The earliest time that gene expression in M+A can be detected is at the 9th day, at least 5 
days later than ECs. This is probably related to different rates of capsid uncoating and 
second strand DNA synthesis of AAV in different cell types[112-115].  
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Figure 3.14 Evaluation of transgene expression in carotid artery at different time points. 
LCA was treated with ultrasound while RCA is used as control. n = 3 or 4 mice each, data 
shown as mean ± s.e.m. EC, endothelial cells; M + A, media and adventitia. 
 Another phenomenon is that the response of M+A to ultrasound treatment is higher 
than that of endothelial cells. At the 4th week, the gene expression of LCA EC is ~19 times 
higher than that of RCA EC, while the gene expression of LCA M+A is ~86 times higher 
than that of RCA M+A. Without ultrasound treatment, gene is also expressed in RCA EC 
at a level significant higher than that in RCA M+A. One possible explanation is that AAV 
have a higher opportunity to contact with AAV. In normal arteries, EC layer is the layer 
that directly contact with the blood, while M+A layer is not easy to contact with materials 
in blood if the EC layer is intact. However, when artery is treated with ultrasound, both EC 
layer and M+A layer have similar opportunities to contact with AAV. 
 One of most important aspects of AAV as a gene vector is its ability to induce 
prolonged gene expression without genome integration. Several studies have shown that 
gene expression by AAV vector could last for several years in human and non-human 
primates[116-118]. The AAV genomes are thought to be persistent in host cells as non-
integrated non-replicating episomes. The persistence of AAV relies on the rate of cell 
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turnover and the number of AAV genomes in the cell. In our study, the gene expression in 
carotid artery could last for over 8 weeks. At the 8th week, the gene expression still remains 
very high. The long persistence of gene expression makes this ultrasound-guided method 
a very useful tool for vascular researches and a promising technique for clinical translation. 
3.3.4 Evaluate the permeability changes of carotid artery with Evans blue 
 Evans blue is an azo dye with a very high affinity for serum albumin. Evans blue is 
often used to evaluate the permeability of BBB to macromolecules. After intravenous 
injection, almost all the dyes are bound to albumin. Since albumin cannot cross the barrier 
in normal condition, normal tissue remains unstained. However, when the BBB is damages, 
albumin-bound Evans blue can enter the tissue. In our previous research, the Evans blue 
can also be used to assess the permeability of carotid artery based on a similar rationale [18].  
 In this experiment, the permeability changes caused by ultrasound treatment in 
carotid artery was also evaluated with Evans blue. As shown in Figure 3.15, Evans blue 
staining immediately post ultrasound treatment in LCA show dark blue staining in LCA 
while RCA remains unstained. This indicates that ultrasound treatment could significantly 
increase the permeability of artery wall. In addition, Evans blue staining at 24 h post 
ultrasound treatment shows that both LCA and RCA were unstained, indicating the 
recovery of permeability. This result is in accordance with the previous results that the gene 
expression reduced significantly when time interval between AAV and MB injection is 24 
h. These results further confirmed our hypothesis that ultrasound treatment could increase 
gene expression by temporally increasing the permeability of carotid artery. 
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Figure 3.15 Permeability changes of carotid artery determined by Evans blue. Ultrasound 
treatment was applied to LCA (MI = 0.4, 1×108 MB/mouse). Evans blue was injected 
intravenously immediately (A) or 24 h (B) post ultrasound treatment. The mice were 
sacrificed 30 min post Evans blue injection and artery trees were dissected out for bright 
field imaging.  
3.3.5 Fluorescence tracking of AAV in carotid artery 
 To further evaluate the behaviour of AAV in carotid artery after system injection, 
AAV9 was labelled with a fluorescent dye Sulf-Cy3-NHS to get AAV-Cy3 (Figure 3.5). It 
has been demonstrated that the fluorescence labelling doesn’t affect both morphology and 
functionality of AAV[109]. After MB injection, the LCA was treated with ultrasound and 
then AAV-Cy3 was injected intravenously. The mice were sacrifice 1 h or 3 h later and the 
carotid artery was then dissected for en face confocal imaging (Figure 3.16-18). 
 At 1 h, the signal of AAV-Cy3 in RCA was predominately detected in the intima 
layer in the form of big bright spots, while the signal in LCA was uniformly dispersed in 
both endothelium and media layer. At 3h, the signal in LCA remains very high, while no 
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significant AAV-Cy3 signal could be detected in RCA. The signal in LCA is about 37 
times higher than that in RCA at 3 h.  
Figure 3.16 Confocal images of mouse carotid artery after ultrasound treatment and AAV-
Cy3 injection. After MB injection, LCA was treat with ultrasound while RCA was set as 
the internal control. Following ultrasound treatment, mice were intravenously injected with 
AAV-Cy3 and sacrificed at 1 h and 3h later, respectively. 
 These results provide a robust evidence to explain why gene expression by AAV 
gene vector is highly enhanced by ultrasound treatment. Without ultrasound treatment, 
most AAVs are initially bind to the endothelial cells as big aggregates. But this kind of 
binding is not stable and most of the bound AAV are flushed away by blood flow. Since 
the endothelium is intact, AAV cannot penetrate the intima layer to enter into media layer. 
This explained why genes encoded by AAV is slightly expressed in endothelial cells but 
not in media and adventitia layer, when ultrasound is not applied.  
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Figure 3.17 Confocal images of carotid artery show the penetration of AAV-Cy3 in carotid 
artery. 
Figure 3.18 Quantification of AAV-Cy3 signals in carotid artery. Data shown as mean ± 
s.e.m. *p < 0.05 as determined by Student's t-test. 
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 However, when ultrasound is applied, the permeability of artery is increased both 
in intima and media and adventitia layer. Therefore, AAV can be well dispersed in the 
intima and media layer. Since the AAV goes deep in the artery, the retained AAV is not 
easy to be flushed away by blood flow, providing enough time for the AAV to be 
internalized by cells. Therefore, gene expression in the ultrasound treated area is much 
higher than that in the untreated area. 
3.3.6 Ultrasound-guided gene delivery to abdominal aorta 
Figure 3.19 Color Doppler ultrasound imaging of abdominal aorta. (A) Paradigm illustrates 
the abdominal aorta separated by renal artery intro two part, suprarenal abdominal aorta 
(SAA) and infrarenal abdominal aorta (IAA). (B) Color Doppler ultrasound imaging shows 
the position of SAA and IAA. The color of Doppler imaging indicates the directions of 
blood flow.  
Abdominal aorta is the largest artery in the abdominal cavity. As part of aorta, it 
supplies blood to most of the organs in abdomen. With several branch points, abdominal 
aorta is one of the most commons sites for developing atherosclerotic plaque [119-121]. 
Another common disease in abdominal aorta is abdominal aortic aneurysm (AAA), which 
is characterized with localized enlargement of abdominal aorta[122-124]. When the diameter 
of aorta is larger than 5.5 cm, the only effective treatment is surgery, which is associated 
with a risk of complication[77, 125]. There are currently no non-invasive treatment options 
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available. Therefore, targeted gene delivery to abdominal aorta is of great significance for 
non-invasive treatment of both atherosclerosis and AAA. 
Figure 3.20 Ultrasound treatment to abdominal aorta. (A) Under the color Doppler 
ultrasound imaging, the structure of the mouse abdominal aorta can be visualized and the 
region of interest can be selected. Then zoom the area of interest so that ultrasound is only 
applied to the selected area. After the microbubble injection, a “blooming” effect can be 
seen in the color Doppler imaging, indicating the destruction of microbubbles. Finally, the 
ultrasound imaging can be switched to the contrast enhanced mode to confirm position of 
the area of interest with very high image quality. (B) After ultrasound treatment, the mouse 
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was injected with Evans blue and sacrificed 30 min later. The blue color in the abdominal 
aorta indicates the permeability changes of abdominal aorta. 
 Under colour Doppler imaging, the whole abdominal aorta of mice can be clearly 
visualized (Figure 3.19). The abdominal can be divided into two part: suprarenal abdominal 
aorta (SAA) and infrarenal abdominal aorta (IAA). The diameter of SAA is larger than 
IAA and IAA is located close to inferior vena cava. Therefore, SAA and IAA shows 
distinct characters in color Doppler images.  
 Firstly, we evaluated if the ultrasound treatment could induce the permeability 
changes of abdominal aorta (Figure 3.20). Under the color Doppler ultrasound imaging, a 
small area in the SAA was selected. After zooming to the selected area, microbubbles were 
injected and microbubbles were destructed in this area. After ultrasound treatment, the 
Evans blue staining was applied. As we can see, a small area in the abdominal aorta is 
stained as blue while other areas are not stained. The size and position of the stained area 
is same as what we can see from the ultrasound imaging. This demonstrated that ultrasound 
treatment can increase permeability of the abdominal aorta. 
Figure 3.21 Experimental design for targeted gene delivery to abdominal aorta. 
 The feasibility of targeted gene delivery with the ultrasound-guided method was 
then evaluated. The mice were divided into two groups (Figure 3.21). After microbubbles 
injection, SAA or IAA was treated with ultrasound imaging. The mice were then injected 
with AAV9 encoding EGFP and sacrificed 4 days later to determine gene expression with 
qPCR. As shown in Figure 3.22, when SAA was treated with ultrasound, the gene 
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expression in SAA was very high while gene expression in IAA was very low. Similarly, 
the gene was only highly expressed in IAA when IAA was treated with ultrasound. This 
result demonstrated the feasibility of using ultrasound-guided method for targeted gene 
delivery to abdominal aorta. 
 Figure 3.22 Expression of EGFP in abdominal aorta as determined with qPCR. Data 
shown as mean ± s.e.m, n=4. 
3.3.7  Ultrasound-guided gene delivery to femoral artery 
 Femoral artery is a large artery in the thigh and controls the blood supply to the leg 
and thigh. The femoral artery gives off several branches, making its susceptible to 
atherosclerosis. When femoral artery is narrowed or blocked by atherosclerosis, people will 
get peripheral artery disease (PAD). The symptoms of PAD include leg pain when walking, 
skin ulcers, bluish skin, and cold skin. The PAD may also cause tissue death which may 
require amputation, ischemic heart disease, heart attack, or stroke. 
 The femoral artery of mouse is a very small artery and hence very hard to be found 
under the colour Doppler mode ultrasound. Therefore, we modified the protocol of 
ultrasound treatment. Firstly the microbubbles were injected and then the femoral 
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bifurcation can be found very easily under the contrast-enhanced mode ultrasound imaging 
(Figure 3.23). The area of interest can be selected from the ultrasound imaging. Then zoom 
to the selected area, switch to colour Doppler mode, and treat the selected area for 30s. The 
permeability of the artery was evaluated with Evans blue staining (Figure 3.24). Without 
ultrasound treatment, the femoral bifurcation is not stained. However, after treating the 
femoral bifurcation with ultrasound, the artery is stained as blue. This indicates that the 
ultrasound treatment can increase the permeability of femoral artery. 
Figure 3.23 Ultrasound imaging of femoral artery. (A) Ultrasound images of the thigh of a 
mouse under the contrast-enhanced mode. The green box indicates the position of femoral 
bifurcation. (B) Color Doppler imaging of the femoral bifurcation during ultrasound 
treatment. (C) Paradigm illustrates the anatomical structure of the artery in the mouse leg. 
The red box indicates the position of femoral bifurcation.  
  The feasibility of targeted gene delivery to femoral artery was further evaluated. 
The right femoral artery (RFA) was treated with ultrasound, while the contralateral left 
femoral artery (LFA) was the control. Following the ultrasound treatment, AAV9-EGFP 
was injected intravenously and the mice were sacrificed 4 days later for qPCR 
measurements. As shown in Figure 3.25, the EGFP expressions in LFA is very low, while 
the gene expression in RFA is about 59 times higher than that in LFA. This result 
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demonstrates that this ultrasound-guided method can be used for targeted gene delivery to 
femoral artery. 
Figure 3.24 Permeability changes of femoral artery as determined by Evans blue staining. 
(A) The femoral artery is not treated with ultrasound. (B) Femoral artery is treated with 
ultrasound. 
Figure 3.25 EGFP expression in femoral artery as determined with qPCR. EGFP 
expression in the femoral artery was checked 4 days post the ultrasound treatment and 
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AAV9-EGFP injection. The right femoral artery (RFA) is treated with ultrasound, while 
left femoral artery (LFA) is not treated. Data shown as mean ± s.e.m, n=4. 
3.4 Summary 
 In this chapter, an ultrasound imaging-guided method for gene delivery to mouse 
was established. This method is based on the hypothesis that AAV can preferentially 
accumulate in the artery that are permeabilized by ultrasound in combination with 
microbubbles. Firstly, the position of the carotid artery can be localized with color Doppler 
ultrasound imaging and the area of interest can be selected by changing the sized and 
position of the color box in the ultrasound images. Then the ultrasound imaging is zoomed 
to the selected area so that ultrasound is only applied in the selected areas. After that, the 
microbubbles will be injected intravenously and the ultrasound used for ultrasound imaging 
can destroy microbubbles, resulting in the increased permeability of the artery. Following 
the ultrasound treatment, the AAV gene vector encoding genes of interest will be injected 
and the gene will be preferentially highly expressed in the ultrasound-treated area. 
 The power of ultrasound and dose of microbubbles were firstly optimized. With 
qPCR measurements, the gene expression in endothelial cells was found to be increased 
with the increasing of ultrasound power and microbubble dose. In addition, two important 
marker genes, ICAM1 and VCAM1, were also determined and no significant difference 
was detected, indicating the safety of the ultrasound treatment. Based on these results, the 
MI at 0.4 and microbubble dose at 1×108/mouse (~5×109/kg) were selected for further 
experiments. 
 Then, the time interval between microbubble and AAV injection was optimized. It 
was found that there was no significant difference in transgene expression if the time 
interval is shorter than 3 h, indicating that the permeability of artery could last for at least 
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3 h. The gene expression reduced significantly when the time interval was longer than 12 
h, indicating that the permeability of artery was mostly recovered post 12 h. 
 The persistence of the gene expression in the carotid artery was also evaluated. The 
gene expression in arterial endothelium could last for at least 8 weeks (longer time is not 
determined). Interestingly, the gene was also expressed in media and adventitia layer but 
started at least 5 days later than endothelium. At the 4th week, the gene expression of 
endothelium in the ultrasound-treated side was ~19 times higher than that in untreated side, 
while the gene expression of media and adventitia layer was increased by ~86 times after 
ultrasound treatment. 
 A mechanism study was conducted to determine why the ultrasound treatment 
could highly increase transgene expression in the carotid artery of mouse. With Evans blue 
staining, the ultrasound treatment was found to temporally increase the permeability of 
artery. By labelling AAV with fluorescent dyes, the distribution of AAV in artery wall was 
determined. Without ultrasound treatment, AAV could only temporally bind to arterial 
endothelium in big aggregates and was flushed away very soon. However, when the artery 
is permeabilized by ultrasound in combination with microbubbles, large amounts of AAV 
could be well dispersed in both intima and media layer and persist for a longer time. These 
results explained the reason why ultrasound in combination with microbubbles could 
highly increase transgene expression in arteries by AAV. 
 Finally the ultrasound-guided method was expanded for targeted gene delivery to 
arteries beyond carotid artery. This method was firstly applied for targeted gene delivery 
to abdominal aorta. Without ultrasound treatment, AAV alone cannot induce significant 
transgene expression in abdominal aorta. However, when ultrasound was applied to 
suprarenal abdominal aorta or infrarenal abdominal aorta, highly enhanced transgene 
expression could be detected in the ultrasound-treated area. As is the case for femoral artery. 
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Ultrasound treatment induced ~59 times higher transgene expression in femoral artery as 
compared with the untreated side. These results demonstrated the potential applications of 
this technology for diseases in abdominal aorta and femoral artery, such as AAA and PAD. 
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CHAPTER 4. TARGETED DELIVERY OF KLK10 TO INHIBIT 
ATHERASCLEROSIS 
4.1 Introduction 
 In the previous chapter, the ultrasound-guided method was demonstrated to be a 
very efficient technology for transgene expression in arterial endothelium. In this chapter, 
this method will be used for targeted transgene expression of KLK10, a novel 
atheraprotective gene identified recently in our lab, to determine if this method can be used 
to inhibit atherosclerosis in the partial carotid ligation (PCL) model. 
4.2 Methods 
4.2.1 Package of KLK10-encoding AAV 
Figure 4.1 Map of plasmid encoding KLK10 for AAV packaging. 
 The KLK10-encoding plasmid was constructed by GENEWIZ (Suzhou, China) and 
confirmed with DNA sequencing (Figure 4.1). The encoding sequence is composed of a 




EGFP through a P2A peptide, which is a “self-cleaving” peptide, so KLK10 and EGFP can 
be separated after translation and their function are not affected. The plasmid was packed 
into AAV by Vigene Biosciences (Jinan, China). 
4.2.2 Mouse partial carotid ligation surgery 
 All animal experiments were approved by the Animal Care and Use Committee at 
Peking University. The partial carotid ligation surgery was conducted as previously 
reported[17]. Male C57BL/6 and ApoE-/- mice (Charles River Laboratories, Beijing) were 
allowed ad libitum to standard chow diet and water until surgery at 8–9 weeks of age. Mice 
were anaesthetized with 3.5% isoflurane initially and then ~2% during the entire procedure. 
Before surgery, analgesic carprofen (5mg/kg) was administrated subcutaneously. The LCA 
bifurcation was exposed by blunt dissection and three caudal branches of LCA (left 
external carotid, internal carotid and occipital arteries) were ligated with 6-0 silk sutures 
while leaving the superior thyroid artery intact. For atherosclerotic studies, the ApoE-/- 
mice were fed with a Paigen’s high fat diet (Research diets) following the surgery until 
killed. C57BL/6 mice were continued with a chow diet. 
4.2.3 En face staining of caratid artery 
 The carotid arteries are excised, fixed in 4% paraformaldehyde, penetrated with 
0.025% Triton X-100 for 10 min, blocked with 10% goat serum for 1 h at room temperature, 
and incubated with primary anti-VCAM1 (Abcam, ab134047) or anti-KLK10 (Boster, 
BA3803-2)  antibodies overnight at 4 ℃. To visualize primary antibodies, Alexa Fluor ® 
594-conjugated goat anti-rabbit antibody (Abcam ab150080) was used for 1 h at room 
temperature. Nuclei were counterstained with DAPI. Samples were imaged using a Nikon 
confocal microscope. 
4.2.4 Serum lipid analysis 
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 Serum lipid analysis was performed by the department of laboratory animal science 
in Peking University Health Science Center for total cholesterol, triglycerides, HDL and 
LDL. 
4.2.5 Plaque lesion analysis 
 Carotid arteries were isolated en bloc from ligated ApoE-/- mice fed with a high fat 
diet for 3 weeks. The artery trees were photographed using a dissection microscope and the 
opaque area covered by plaque and total area of LCA were quantified using NIH ImageJ 
software 
4.2.6 Elisa 
 The serum KLK10 level was determined with a mouse KLK10 Elisa kit from 
Mybiosource following the manufacturer’s instructions. 
4.2.7 Immunohistochemistry     
 Arteries were embedded in optimal cutting temperature compound (Tissue-Tek), 
frozen on dry ice and stored at -80 ℃ until used. To visualize atherosclerosis development, 
Oil-red-O staining was carried out. Frozen sections were fixed in formalin for 10 min, 
rinsed with water and 60% propylene glycol, and then stained with Oil Red O staining 
solution (Solarbio). Slides were then differentiated in 60% propylene glycol, rinsed with 
distilled water, and counterstaining was done using Mayer’s haematoxylin (Beijing 
Leagene Biotechnology Co., Ltd.) for 5 min. 
 For VCAM1 and CD45 staining, sections were fixed in a 1:1 mixture of 
methanol/acetone for 10 min at room temperature (RT) and then blocked using 10% (v/v) 
goat serum in TBS (2 h, at RT). Immunohistochemical staining was conducted anti-
VCAM1 (Abcam ab134047) or anti-CD45-biotin (eBioscience) overnight at 4 ℃ . 
Secondary staining for VCAM1 was performed using Alexa Fluor ® 594-conjugated goat 
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anti-rabbit antibody (Abcam ab150080) while Alexa Fluor ® 594-conjugated streptavidin 
(Bioss) was used for CD45. Nuclei were counterstained with DAPI. Samples were imaged 
using an Axio Scan.Z1 Slide Scanner (Zeiss). 
4.3 Results and Discussion 
4.3.1 Dose-dependent effect of AAV9-KLK10 
 To evaluate if the ultrasound-guided method can be used for targeted transgene 
expression, KLK10-encoding AAV9 was constructed. The coding sequence contains a 
CAG promoter, cDNA sequence of KLK10, and EGFP sequence. Between KLK10 and 
EGFP, a P2A peptide was added to make KLK10 and EGFP translated simultaneously. 
The P2A peptide is a “self-cleaving” peptide, which undergoes self-cleavage to generate 
mature viral proteins by a translational effect that is known as “stop-go” or “stop-carry”[106-
108]. The cleavage site is located between the last glycine of its C-terminal and the first 
praline of the downstream protein. The incorporation of P2A makes the genes co-expressed 
while their function are not affected. Therefore, the level of EGFP expression should reflect 
how much KLK10 is the result of exogenous expression. 
 The expression of KLK10 is significantly reduced in the arterial endothelium that 
is affected by d-flow. In the PCL model, KLK10 expression of LCA is much reduced as 
compared with RCA. Therefore, this model was used to optimize the dose of AAV9-
KLK10. Following microbubbles injection, the ultrasound was applied to LCA and then 
AAV9-KLK10 was injected intravenously at three different doses. Two days post the 
treatment, the PCL surgery was conducted. 3 days after the surgery, the mice were 
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sacrificed and the carotid endothelial cells were isolated for qPCR measurements (Figure 
4.2). 
Figure 4.2. Experimental design for optimizing dose of AAV9-KLK10 in the PCL model. 
 As shown in Figure 4.3, the EGFP expression in LCA is dependent on the dose of 
AAV9-KLK10 while the expression in RCA remains very low, demonstrating that 
targeting ability of this ultrasound-guided method. Since EGFP is co-expressed with 
KLK10, a similar trend is also found in KLK10 expression of LCA. With partial carotid 
ligation surgery, the KLK10 expression in LCA is much reduced as compared with that in 
RCA. With a dose of AAV9-KLKL10 at 5×1011 vg/mouse, the KLK10 expression in LCA 
is recovered and not significantly different from that in RCA. Therefore, 5×1011 vg/mouse 
(~2.5×1013 vg/kg) is selected for further experiments. 
 Interestingly, with the increasing of dose of AAV9-KLK10, although the 
expression of EGFP in RCA is slightly increased, the KLK10 expression in RCA is reduced. 
This indicated that AAV9-KLK10 at high dose might have some side effects. Although 
AAV alone without ultrasound can induce a weak transgene expression in the endothelial 
cells as shown in the previous chapter, such a weak transgene expression in normal dose 
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cannot be used for therapeutic applications and high dose will induce adverse effects. This 
highlights the advantage of the ultrasound-guided method, inducing very high KLK10 
expression with a relatively low dose of AAV9-KLK10. 
Figure 4.3 EGFP and KLK10 expression of carotid endothelium with different dose of 
AAV9-KLK10. 
4.3.2 The role of US, MB, and AAV-KLK10 
Figure 4.4 Experimental design for determining the role of US, MB, and AAV-KLK10. 
  To demonstrate the indispensable role of ultrasound, microbubbles and AAV9-
KLK10, four additional groups was conducted: control (saline only), US&MB only, 
AAV9-EGFP + US&MB, and AAV9-KLK10 only (Figure 4.4).  As expected, in the 
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control group, KLK10 expression in LCA is significantly downregulated, similar to our 
previous report (Figure 4.5)[42]. In addition, compared with the control group, US&MB 
only, AAV9-EGFP + US&MB, and AAV9-KLK10 only didn’t induce any significant 
changes of KLK10 expression in both LCA and RCA. However, AAV9-KLK10 in 
combination with US&MB could recover the KLK10 expression in LCA to a level 
comparable to RCA, while the KLK10 expression in RCA was not significantly changed. 
These results demonstrate that AAV9-KLK10 in combination with US&MB could be used 
for targeted delivery of KLK10 gene and either of them are dispensable. 
Figure 4.5 KLK10 expression of carotid endothelium with different treatments. 
 The targeted expression of KLK10 was further demonstrated with 
immunofluorescence staining. As shown Figure 4.6, the KLK10 expression of LCA in the 
control group is lower than that of RCA, which is correlated with the qPCR results. The 
AAV9-KLK10+US&MB treatment could significantly increase KLK10 expression in 
 79 
LCA. Since KLK10 is a very important atheroprotective gene, the increased KLK10 
expression is expected to attenuate inflammation in LCA. Therefore, the arteries were also 
stained with VCAM1 antibody. The VCAM1 expression of LCA in the control group was 
much increased and the AAV9-KLK10+US&MB treatment could reduce VCAM1 
expression in LCA (Figure 4.7). These result demonstrated that ultrasound-guided method 
can be used for targeted delivery of KLK10 and inhibiting inflammation in areas affected 
by d-flow. 
Figure 4.6 En face KLK10 staining of carotid artery. Two days before the PCL surgery, 
the mice were treated with AAV9-KLK10+US&MB, while the control mice were injected 
with saline only. The mice were sacrificed three days post PCL surgery. The carotid arteries 
were stained with KLK10 antibody and en face confocal imaged.  
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Figure 4.7 En face VCAM1 staining of carotid artery. Two days before the PCL surgery, 
the mice were treated with AAV9-KLK10+US&MB, while the control mice were injected 
with saline only. The mice were sacrificed three days post PCL surgery. The carotid arteries 
were stained with VCAM1 antibody and en face confocal imaged. 
4.3.3 Atherosclerotic studies 
 The targeted delivery of KLK10 with the ultrasound-guided method was further 
characterized to see if atherosclerotic development could be inhibited in this way (Figure 
4.8). After partial carotid ligation surgery and high fat diet for 3 weeks in ApoE-/- mice, the 
atherosclerotic plaques rapidly develop in LCA. Two days before the PCL surgery, the 
mice were treated with US&MB followed by AAV9-KLK10 injection (5×1011vg/mouse), 
while the control mice were injected with saline only. After a high fat diet for 3 weeks, the 
mice were sacrificed for atherosclerotic analysis.  
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Figure 4.8 Experimental design of the atherosclerotic studies. 
 The carotid artery trees were dissected out and imaged under the bright field 
imaging. The opaque area covered by plaque can be visualized. The atherosclerotic lesion 
area is determined as the percent of opaque area divided by the total area of LCA. With 
targeted KLK10 delivery, the atherosclerotic lesion area was decreased from 70.1±6.0% 
to 32.2±4.9% (Figure 4.9) and the atherosclerotic lesion area was decreased by ~37.9%. 
 The frozen sectioning was then conducted from the middle part and then stained 
with Oil-Red-O. Oil-Red-O is a fat-soluble dye commonly used for staining of neutral 
triglycerides and lipids on the frozen sections. The Oil-Red-O staining can make fat more 
visible. The atherosclerotic plaque is characterized by accumulation of lipids in the artery 
wall, together with infiltration of immunocytes, such as macrophages, and the formation 
of a fibrous cap by vascular smooth muscle cells. As shown in Figure 4.10，the plaque 
size determined by Oil-Red-O staining was decreased by 89.8%. 
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Figure 4.9. Atherosclerotic lesion analysis of carotid arteries. Two days before the PCL 
surgery, the mice were treated with AAV9-KLK10+US&MB (KLK10), while the control 
mice were injected with saline only. After PCL surgery, mice were fed with high fat diet 
for 3 weeks. The artery trees were dissected out and imaged with the bright field imaging 
(A). The lesion are quantified (B).  n =9 each, data shown as mean ± s.e.m.; ***p<0.001 
as determined by student’s t-test. The while boxes in (A) indicated the sites where frozen 
sections is conducted. 
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Figure 4.10 Oil-Red-O staining. The frozen sections are prepared from the middle parts of 
LCA and stained with Oil Red O. The images are collected with the bright field imaging 
(A). The plaque sized are quantified (B). n =9 each, data shown as mean ± s.e.m.; 
***p<0.001 as determined by student’s t-test.  
 84 
Figure 4.11 VCAM1 staining. The frozen sections are prepared from the middle parts of 
LCA and stained with CD45 antibody. The images are collected with the fluorescence 
imaging (A). The expression of CD45 are quantified (B).   n =9 each, data shown as mean 
± s.e.m.; *p<0.05 as determined by student’s t-test.  
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Figure 4.12 CD45 staining. The frozen sections are prepared from the middle parts of LCA 
and stained with CD45 antibody. The images are collected with the fluorescence imaging 
(A). The expression of CD45 are quantified (B).   n =9 each, data shown as mean ± s.e.m.; 
**p<0.005 as determined by student’s t-test.  
 The VAM1 protein is highly expressed in the inflamed arterial endothelium and 
mediates recruiting lymphocytes, monocytes, eosinophils, and basophils to vascular 
endothelium, which is important in the initialization and progressing of the atherosclerosis. 
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KLK10 is a atherprotective gene and the expression of KLK10 is expected to reduce the 
VCAM1 expression and inhibit atherosclerosis. Therefore, the frozen sections were also 
stained with VCAM1 antibody. As shown in Figure 4.11, the VCAM1 expression was 
decreased by 59.7% after the targeted delivery of KLK10 
Figure 4.13 Plasma lipid profiles. Blood was collected immediately following sacrifice and 
the plasma was obtained then. The samples were then to measure triglycerides, high-
density lipoprotein (HDL), total cholesterol, and low-density lipoprotein (LDL). n =9 each, 
data shown as mean ± s.e.m.; ns, p>0.05as determined by student’s t-test.  
 Immunocytes, such as macrophages, play a pivotal role in the initialization and 
development of atherosclerosis. Macrophages can internalize cholesterol and become lipid-
laden cells with a foamy appearance. The foamy macrophages contribute to all stages of 
atherosclerosis. The CD45 is one maker genes of immunocytes. Therefore, the CD45 
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expression can reflect the infiltration of immunocytes. As shown in Figure 4.12, the 
targeted delivery of KLK10 reduced the CD45 expression by 78.6%. 
 The hypercholesterolemia is the one of the major cause of atherosclerotic 
development by in ApoE-/- mice. To rule out the possibility that the reduction in 
atherosclerosis is the results of changes in plasma lipid profiles, the triglycerides, high-
density lipoprotein (HDL), total cholesterol, and low-density lipoprotein (LDL) in both 
groups were determined. As shown in the Figure 4.13, no significant differences were 
found in the all the measurements. 
Figure 4.14 Plasma KLK10 level. The KLK10 level in the plasma was measured with a 
commercial ELISA Kit. n =9 each, data shown as mean ± s.e.m.; ns, p>0.05 as determined 
by student’s t-test.   
 In our previous research, the elevation of KLK10 level in serum was demonstrated 
to be able to inhibit atherosclerotic development. Therefore, in this study, the plasma level 
of KLK10 was also measured with ELISA. NO significant difference was found in respect 
to plasma KLK10 concentration in both groups (Figure 47). This result demonstrated that 
the inhibited atherosclerotic development was a result of localized transgene expression of 
KLK10 in carotid artery. 
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 Furthermore，after the sacrifice of the mice, the major organs including heart, liver, 
spleen, lung, kidney, and thymus in both groups were dissected, sectioned, and subjected 
to H&E staining. Compared with the control group, the microbubble, ultrasound, and 
AAV9-KLK10 treatment didn’t induce any significant changes in these organs (Figure 
4.15). This results demonstrated the safety of the targeted gene delivery KLK10 for the 
treatment of atherosclerosis 
Figure 4.15 H&E staining of the major organs.  
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4.4 Summary 
 In this chapter, the ultrasound-guided method of gene delivery was investigated for 
the targeted delivery of KLK10 in the PCL model. After PCL surgery, the KLK10 
expression in LCA is reduced compared with the RCA. After treating LCA with ultrasound 
combining with microbubbles, KLK10-encoding AAV9 at a dose of 2.5×1013vg/kg could 
increase the expression of KLK10 in LCA to a level comparable to that in RCA. In the 
atherosclerotic studies, the targeted delivery of KLK10 gene with this technology could 
significantly reduce the plaque size, CD45, and VCAM1 expression. In addition, no 
significant difference in respect to plasm lipid profile, plasma KLK10, and H&E staining 
of major organs was found. These results demonstrate the atheroprotective role of KLK10 
and highlight the potential of the ultrasound-guided method of gene delivery in respected 
to applications for therapy of artery diseases. 
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CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS 
5.1 Conclusion 
 In this thesis, we established two technologies for ultrasound-enhance KLK10 
delivery to inhibit atherosclerosis. In the first method, plasmid and microbubbles are 
intramuscularly injected in skeletal muscle. The ultrasound are then applied to injecting 
site to induce highly enhanced transgene expression in skeletal muscle. KLK10 expressed 
in the skeletal muscle can be secreted out and enter into the blood to act on the endothelial 
cells. In the second method, AAV gene vector, microbubbles and ultrasound imaging are 
combined for targeted gene delivery to mouse artery in a non-invasive and imaging-guided 
way. With color Doppler imaging, the anatomical structure of artery can be visualized and 
the area of interest can be selected so that ultrasound only irradiate the selected area. After 
microbubbles injection, the ultrasound can destroy the microbubbles only in the selected 
areas, resulting in increased permeability of the artery. Following system administration, 
AAV gene vector can preferentially accumulate in the ultrasound-treated area, leading to 
highly enhanced transgene expression. Both methods have been demonstrated to be able to 
deliver KLK10 in vivo and inhibit atherosclerosis development in the PCL model. 
Advantages and disadvantages of this technology are briefly listed below 
5.1.1 Ultrasound-enhanced transgene expression in skeletal muscle 
5.1.1.1 Advantages 
(1) No-viral gene delivery 
 Gene transfer for gene therapy is a rapidly expanding field. However, most of the 
clinical trials for gene therapy are using virus gene vectors. Although the efficacy of virus 
is relatively higher in several applications, the immunogenicity and high price of virus are 
the major defects. Therefore, developing non-viral methods for gene delivery is 
continuously pursued by researchers. In this research, a non-viral method for transgene 
expression in skeletal muscle is established for the therapy of atherosclerosis. Utilizing the 
sonoporation effect of microbubble destruction, the efficacy of gene transfer by naked 
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plasmid can be enhanced. Since this kind of gene delivery is not immunogenicity, repeated 
administration is feasible  
(2) Persistent transgene expression 
 Although systematic administration of recombinant KLK10 protein can inhibit 
atherosclerosis, repeated injection is needed owing to the short circulation time of 
recombinant protein. By the transgene expression of KLK10 in skeletal muscle, the KLK10 
protein can be produced by the muscle cells and secreted into blood. With one injection, 
the gene expression can persist for over 3 weeks. 
5.1.1.2 Disadvantages 
(1) Potential adverse effects to normal tissues 
 Although the transgene expression of KLK10 in skeletal muscle can inhibit 
atherosclerosis, the expressed KLK10 proteins can act on the whole body, not the artery 
endothelium alone, which may cause some unexpected side effects to normal tissues. 
(2) Inconsistent transfection efficacy 
 Although the average efficacy of gene transfer can be enhanced the sonoporation 
effect, the transfection efficacy is inconsistent and the gene transfer is not always 
successful. The variability of expression is probably due to non-uniform distribution of 
substances injected in the skeletal muscle[126]. Increasing the proficiency of operators might 
partly solve this issue. 
5.1.2 Ultrasound-imaging-guided transgene expression in artery 
5.1.2.1 Advantages 
(1) No-invasive gene delivery 
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 Targeted gene expression to arterial cells in vivo is a hard task before this research. 
One of the most common strategy is to temporally block the blood flow in artery and 
directly inject gene vector in the lumen [127]. However, this kind of methods require 
complicated surgery procedures and may cause very serious complications to the animals. 
With the technology established in this research, no surgical expertise is required and local 
delivery of high level of transgenic proteins comparable to that by surgery can be achieved 
in a non-invasive way. 
(2) Image-guided gene delivery 
 With ultrasound imaging, the anatomical structure of arteries can be visualized and 
areas of interest can be selected so that the gene is only expressed in the selected areas. 
Since the ultrasound imaging is the most common imaging for artery disease, it’s very 
promising to combine this technique with ultrasound imaging to achieve the theranostics 
of arterial diseases. With this technique, we can deliver the genes to any part of the arteries 
as we need. 
(3) No complex chemical modification 
 One of the most common strategy for targeted delivery is to modify the vectors to 
targeting ligands. However, this strategy usually requires complex chemical procedures, 
which is not that attainable for regular biomedical researchers. With the ultrasound-guided 
method, both microbubbles and AAV are commercially available and most of the 
biomedical researchers can use it very easily. 
(4) Universality 
 In this thesis, the ultrasound-guided method of gene delivery was tested for targeted 
delivery to carotid, abdominal aorta, and femoral artery. In theory, this technology may be 
further expanded for other part of arteries, veins, etc. 
(5) High specificity 
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With the ultrasound-guided method, the transgene expression in the targeted area 
could be increased by as high as 85 fold, which is hard-to-achieve by any other methods. 
5.1.2.2 Disadvantages 
(1) Immunogenic 
 One of the biggest problems of virus gene vectors is that antibody will be generated 
after injection. Therefore, virus vector is only effective for the first administration. For 
multiple injections, the serotype of virus need to be changed 
(2) Off-target effects 
 Although the ultrasound treatment could highly increase the accumulation of AAV 
in the targeted area, the retention of AAV in other organs especially liver is not affected. 
This issue might be solved by modifying the viral capsid or replacing the promoter to a 
cell-specific one. 
5.2 Future Scientific Directions 
 Several future scientific directions are presented here regarding further 
development and applications of the technologies established in this thesis. 
(1) The efficacy of gene transfer in skeletal muscle may be further increased. 
 After intramuscular injection, the plasmid and microbubbles are mostly located in 
the injecting sites. Therefore, the gene is mostly expressed in the cells close to the injecting 
sites. Therefore, if the microbubbles and plasmid can be dispersed in the muscle, the 
efficacy of gene transfer might be increased. 
(2) The AAV gene vectors may be replaced with a non-viral gene vectors, such as 
liposome, polymer nanoparticles, etc. 
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 Although AAV gene vector is very effective for gene delivery, it is immunogenic 
and very expensive, which may limit its further applications. Therefore, its’s necessary to 
replace the AAV a non-viral gene vector, even though the efficacy might be compromised. 
(3) The targeting specificity of ultrasound-imaging-based technology may be further 
improved by modifying the viral capsid or replacing the promoter to a cell-specific 
one. 
 With the ultrasound-imaging-based method for gene delivery, the external gene can 
be selectively delivered the selected artery. However, the endothelial cell is not the only 
cell type that is transfected. It is possible to achieve cell-specific gene delivery by 
modifying the viral capsid or replacing the promoter to a cell-specific one. 
(4) The technologies might be used for therapy of other vascular diseases. 
 For the first technology, the protein expressed in skeletal muscle is secreted into 
blood and act on the whole body. Therefore, it is possible to apply this technology for the 
therapy of other artery diseases using secreted proteins. 
 The ultrasound-guided method of gene delivery was tested for targeted delivery to 
carotid, abdominal aorta, and femoral artery. In theory, this technology may be further 
expanded for other part of arteries, veins, etc. 
5.3 Summary 
 In this chapter, advantages and disadvantages of the ultrasound-guided methods for 
transgene expression in vivo are summarized and some future scientific directions are 
proposed. 
 Targeted gene expression to arterial cells in vivo is a hard task before this research. 
This thesis introduced two simple but effective methods for non-invasive gene delivery to 
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inhibit atherosclerosis utilizing the sonoporation effect by ultrasound and microbubbles. In 
the first method, plasmid and microbubbles are intramuscularly injected in skeletal muscle. 
The ultrasound are then applied to injecting site to induce highly enhanced transgene 
expression in skeletal muscle. The ultrasound are then applied to injecting site to induce 
highly enhanced transgene expression in skeletal muscle. KLK10 expressed in the skeletal 
muscle can be secreted out and enter into the blood to act on the endothelial cells. This 
strategy might also be applicable for the gene delivery of other secreted protein. Although 
this method is effective in inhibiting atherosclerosis, the potential off-target effects and 
inconsistent efficiency might limit its further applications. 
 In the second method, AAV gene vector, microbubbles and ultrasound imaging are 
combined for targeted gene delivery to mouse artery in a non-invasive and imaging-guided 
way. With color Doppler imaging, the anatomical structure of artery can be visualized and 
the area of interest can be selected so that ultrasound only irradiate the selected area. After 
microbubbles injection, the ultrasound can destroy the microbubbles only in the selected 
areas, resulting increased permeability of the artery. Following system administration, 
AAV gene vector can preferentially accumulate in the ultrasound-treated area, resulting in 
highly enhanced transgene expression. The targeted delivery of KLK10 in this method 
could efficiently inhibit atherosclersosis. Although the targeting efficacy and specificity is 
extremely high, the potential immunogenicity and off-targets still need to further 
improvement. 
 In summary, this thesis established two technologies for transgene expression of 
KLK10 in vivo to inhibit atherosclerosis. This research not only highlights the potential of 
KLK10 for the gene therapy of atherosclerosis, but also provides two important methods 
of gene delivery, which may find their broad applications in fundamental studies and 
clinical translation in respect to artery diseases, such as atherosclerosis, AAA, and PAD. 
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However, these technologies are far from perfect and a lot of works still need to be done 




APPENDIX A. PLASMID MAP 
A.1  pCMV-Luc 
A.2  pCMV-Igκ-Luc 
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A.3  pCMV-KLK10-T2A-Luc 
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